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Abstract 
 
Cloning cattle using somatic cell nuclear transfer (SCNT) is an inefficient process, 
with approximately only 5% of transferred embryos developing to live offspring. 
SCNT produced cattle have a high mortality rate due to a number of 
developmental abnormalities caused mainly by the incorrect epigenetic 
reprogramming of the donor cell to a pluripotent state. Conventional bovine 
SCNT involves fusion of a somatic donor cell into an enucleated metaphase II 
(MII) arrested oocyte. The resulting embryo is cultured to the blastocyst stage 
before being transferred to a surrogate cow to produce live offspring. Zygotes 
were initially thought to be unsuitable as SCNT recipients in bovine, until it was 
revealed that using telophase II (TII) zygotes as opposed to MII oocytes results in 
improved in vivo development. Metaphase zygotes have also been used 
successfully as SCNT recipients in mouse to produce cloned blastocysts and it has 
been proposed that reprogramming factors sequester in the pronuclei of interphase 
zygotes. Little is known about the nature the nuclear reprogramming, however a 
few candidate reprogramming factors have emerged recently. TCTP is known to 
activate key pluripotency genes (POU5F1 and NANOG) in somatic cell nuclei. It 
has also been identified as present in bovine oocytes with a high potential to 
reprogram somatic cells. Reprogramming of cell nuclei by Xenopus egg extract 
has found to require BRG1. Immunodepletion of BRG1 was shown to decrease 
the reprogramming ability of the egg extract, whist its over-expression increased 
reprogramming potential. HDAC1 has been found to initiate a transcriptionally 
repressive state in preimplantation mouse embryos possibly inhibiting 
transcription of reprogramming factors. Knockdown of HDAC1 using TSA is 
known to increase development of mouse NT embryos.  
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The aim of this study was to produce blastocysts using metaphase zygotes as 
recipients for SCNT in bovine. In addition, localisation and abundance of 
candidate reprogramming factors TCTP (TPT1 gene), BRG1 and HDAC1 were 
examined in MII oocytes as well as TII, interphase and metaphase zygotes. 
 
This study found metaphase zygotes are unsuitable as recipients for bovine SCNT 
using current methodologies, possibly due to the premature cleavage of the 
embryos. Control embryos produced using MII oocytes as recipients developed to 
blastocyst with an efficiency of ~ 11%. mRNA analysis of zygotes and oocytes 
did not reveal any significant differences in the relative concentrations of TPT1 or 
BRG1 between the samples. The TCTP and HDAC1 proteins showed a similar 
pattern of localisation in the MII oocytes and all stages of zygotes. Both proteins 
clearly localise to the maternal chromatin in the second polar body of TII zygotes. 
This finding has never previously been described and may in part explain why 
there is increased cloning efficiency observed when using TII zygotes as SCNT 
recipients. 
 
This increased understanding of these reprogramming factors may increase our 
knowledge of the processes which occur during NT and lead to greater efficiency 
of bovine cloning for commercial and therapeutic purposes. 
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1. Introduction 
 
1.1 General introduction 
Cloning cattle using Somatic Cell Nuclear Transfer (SCNT) is an inefficient 
process, where the surviving offspring only represent approximately 5% of the 
embryos transferred into the surrogate cow (Oback and Wells, 2003). Nuclear 
transfer (NT) involves adult donor cells being attached to enucleated MII oocytes 
(cytoplasts) then electrically fused at room temperature before placement of the 
fused couplets into in vitro culture drops (Schurmann et al., 2006). These clones 
have a high mortality rate due to suffering a number of developmental 
abnormalities such as higher birth weights, muscular-skeletal problems and 
incorrect placental formation (Wells et al., 2004).  At the cellular level, a higher 
incidence of apoptosis (Park et al., 2004) and aberrant allocation of inner cell 
mass (ICM) (Koo et al., 2002) is evident. At the sub-cellular level, problems with 
DNA methylation patterns (Bourc'his et al., 2001) and the dysregulation of genes 
occurs (Humpherys et al., 2002). These abnormalities are referred to as the 
“Cloning Syndrome” and are thought to mainly be due to epigenetic defects 
(changes in chromatin structure, not involving a change in DNA base sequence) 
which occur during cell reprogramming, where the donor cell DNA is 
reprogrammed to a pluripotent embryonic state (Schurmann et al., 2006). 
 
Zygotes were initially thought to be unsuitable for use in NT experiments as they 
could not support reprogramming of the donor nucleus (McGrath and Solter, 
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1984), whereas an unfertilised oocyte could (Kato et al., 1998). This suggests that 
factors essential for the correct reprogramming of the donor nucleus are lost to the 
oocyte cytoplasm upon fertilisation (McGrath and Solter, 1984). However, a study 
by Schurmann, Wells et al. (2006) revealed that early zygotes (in the telophase II 
stage) were suitable for bovine somatic cell NT and resulted in higher in vivo 
development of cloned offspring. At present, there is no evidence suggesting that 
MII or Telophase II (TII) zygote cytoplast recipients differ in their ability to 
reprogram a somatic cell (Oback, 2008). Egli, Rosains et al. (2007) then 
investigated the possibility that factors required for reprogramming or embryonic 
development located in the unfertilised oocyte become sequestered in the 
pronuclei of interphase zygotes. This could explain why zygotes enucleated in 
interphase cannot support development after NT, as removal of the pronuclei 
would also mean removal of the reprogramming factors. In these experiments, 
mouse zygotes were arrested in the metaphase stage of mitosis (where breakdown 
of the pronuclear envelope occurs, possibly releasing the reprogramming factors) 
using nocodazole. The metaphase nuclei were then removed and the resulting 
cytoplasts injected with donor cell chromosomes (Egli et al., 2007). It was found 
that these metaphase arrested zygotes injected with donor cells developed to the 
blastocyst stage, indicating they supported complete reprogramming of donor 
DNA. These results suggest that at least some of the reprogramming factors were 
not permanently lost from the oocyte following fertilisation, and may localise to 
the pronuclei at interphase (Egli et al., 2007). 
 
Egli et al. (2008) proposed that the developmental potential of a cell is determined 
by its transcriptional profile. Transcriptional regulators may dissociate from the 
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chromatin on entry into mitosis and reassociate with the chromatin following cell 
division, meaning new gene expression patterns are established (Egli et al., 2008). 
Transcriptional silencing in mitosis may be due to the condensed structure of the 
chromatin, and therefore provide an opportunity for changes in gene expression. 
Dissociation of transcriptional regulators from the chromatin during mitosis (and 
not interphase) may allow these factors to disperse into the cytoplasm. This would 
provide an opportunity to remove the genome of the mitotic zygote or oocyte 
which can then be used as a recipient for NT, leaving main factors that allow for 
the resetting of transcriptional profiles in the donor cell remaining in the recipient 
cytoplasm (Egli et al., 2008). Transcriptional profiles which regulate genes within 
a cell are flexible and reversible. When an adult cell is transferred into an 
unfertilised oocyte, the transcriptional machinery of the cell alters and becomes 
embryonic in nature (Beyhan et al., 2007; Brambrink et al., 2006). The molecular 
mechanisms underlying epigenetic reprogramming are still essentially a black box. 
No definitive reprogramming factors have so far been purified (Bortvin et al., 
2003). 
 
Candidate reprogramming factors analysed in this study are tumour translationally 
controlled protein 1 (TCTP); the gene of which is TPT1 (Koziol et al., 2007), 
brahma-related gene 1 (BRG1) (Hansis et al., 2004) and Histone Deacetylase 1 
(HDAC1) (Ma and Schultz, 2008).  
 
TCTP has been found to activate transcription of POU5F1 (also known as OCT4) 
and the NANOG (transcription factors which are both implicated in inducing 
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pluripotency of cells) (Koziol et al., 2007). It was found that a reduction in the 
oocyte content of TCTP reduced POU5F1 transcription, suggesting TCTP is 
involved in the transcriptional activation of POU5F1 (Koziol et al., 2007). 
POU5F1 is normally expressed only in pluripotent cells (Byrne et al., 2003). It is 
activated during NT into oocytes and activation of POU5F1 transcription is 
directly correlated to cloning efficiency (Bortvin et al., 2003). A reduction in 
NANOG also occurs after a down regulation of TPT1 in oocytes, suggesting TPT1 
is also involved in the activation of NANOG transcription (Koziol et al., 2007). 
NANOG is thought to be an important pluripotency gene as its over-expression 
results in a significant increase of the nuclear reprogramming efficiency in cell 
fusion experiments (Silva et al., 2006). TCTP was found to bind to the POU5F1 
promoter, but not significantly to the NANOG promoter. This implies that TCTP 
regulates NANOG transcription indirectly, while it directly activates POU5F1 
transcription (Koziol et al., 2007). The correct activation of the POU5F1 and 
NANOG genes is essential for correct nuclear reprogramming (Koziol et al., 2007). 
 
Hansis, Barreto et al. (2004) looked to identify some genes and mechanisms 
involved with nuclear reprogramming in Xenopus egg extract. It was found that 
the pluripotency markers OCT4 and Germ Cell Alkaline Phosphatase (GCAP) 
were up regulated in human 293T cells and human primary leukocytes, exposed to 
the egg extract. A screen was carried out to identify potential factors involved in 
the reprogramming process, and the chromatin remodelling ATPase BRG1 was 
discovered to have a major influence. Immunodepletion of BRG1 inhibited the 
oocytes ability to reprogram, whilst its overexpression increased the oocyte’s 
ability to reprogram as the embryo progressed further through development 
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(Hansis et al., 2004). The chromatin remodelling factor BRG1 has been shown to 
dissociate from the chromatin during mitosis (Egli et al., 2008),  meaning it is an 
important gene to consider for influencing donor cell reprogramming and 
development of metaphase zygote NT embryos. 
 
Acetylation of histones plays a major role in regulating transcription in eukaryotic 
cells. Hyperacetylation of chromatin is associated with increased gene expression, 
possibly due to the unwinding of the nucleosome structure allowing better access 
of transcription factors. Histone Deacetylases (HDACs) are associated with the 
silencing of gene expression as they deacetylate histones by interacting with the 
gene promoter (Grozinger and Schreiber, 2002). HDAC1 is likely a major 
deacetylase in early mouse embryos, and is thought to be specifically involved in 
the deacetylation of histone H4K5 (Ma and Schultz, 2008). Ma and Schultz (2008) 
also discovered that HDAC1 is involved in initiating a transcriptionally repressive 
state, and is highly abundant in pre-implantation mouse embryos. 
 
Exposure of activated NT reconstructs to HDAC inhibitors such as trichostatin A 
(TSA) can increase the efficiency of SCNT by preventing abnormal 
hypermethylation of histones in early mouse embryos (Kishigami et al., 2006). 
This provides an example of how inhibition of HDACs can lead to an 
improvement in epigenetic reprogramming of SCNT embryos. 
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Identification and quantification of these candidate reprogramming factors in the 
developing zygote will result in a better understanding of the epigenetic 
remodelling processes in cloned embryos. Better understanding of these processes 
may lead to increases in cloning efficiency and ultimately being able to use 
cloning for commercial and therapeutic purposes. 
 
1.2 Metaphase zygote NT experiments 
McGrath and Soulter (1984) transferred mouse embryonic nuclei into enucleated 
zygotes and concluded that development of these reconstructs was unable to be 
supported in vitro (McGrath and Solter, 1984). Several more attempts have been 
carried out in a variety of species using zygotes as recipients for NT; including 
rabbit (Modlinski and Smorag, 1991), pig (Prather and First, 1990) and rhesus 
(Meng et al., 1997).  In all cases the vast majority of embryos produced unable to 
progress past the first two cleavage divisions (Greda et al., 2006). Wakayama, 
Tateno et al. (2000) concluded that when interphase mouse zygotes were used as 
recipients for SCNT, no development to blastocyst was observed (Wakayama et 
al., 2000). 
 
Schurmann, Wells et al. (2006) found that by using early zygotic cytoplasts at the 
TII stage as NT recipients, in vitro development was similar to that of NT into 
metaphase II cytoplasts, however in vivo development was significantly increased. 
They concluded the reason for this increased development was that certain factors 
are delivered to the oocyte by the sperm during natural fertilisation (not artificial 
activation), leading to an increase in in vivo development. These factors may 
include phospholipase C, which in mouse spermatozoa induces long lasting Ca2+ 
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oscillations in the egg (Parrington et al., 2000) rather that the single large Ca2+ rise 
brought about by artificial activation . Also, the centrosome present in bovine 
oocytes may be removed during enucleation in standard NT experiments 
(Schurmann et al., 2006), and 3000 kinds of mRNA (Ostermeier et al., 2002) 
some that are delivered to the oocyte post fertilisation (Ostermeier et al., 2004). 
Micro RNAs delivered by the sperm (Ostermeier et al., 2005) may also play a role 
in the increased in vivo development as well as possible sperm derived transcripts 
which may arise during the fusion of the sperm and the oocyte (Schurmann et al., 
2006).  
 
Normal fertilisation (fig 1.1) involves sperm entering an MII oocyte to form a 
zygote, which then progresses through the anaphase II and telophase II cell cycle 
stages extruding a second polar body in the process. After formation of the second 
polar body the zygote progresses through the G1 and S phases before again 
entering metaphase prior to cleavage (27 – 33 hpf). During NT of a somatic donor 
cell into an MII cytoplast (fig 1.2), the same series of events occur as in fig 1.1 but 
the reconstruct must be artificially activated. The embryo progresses to the 
metaphase stage before cleaving into a two cell approximately 25 hours post 
activation. When metaphase arrested zygotes are used as NT recipients (fig 1.3), 
the zygote has already progressed through the G1 and S phases which occur 
during normal fertilisation. It can be assumed following NT the zygote will again 
progress through the anaphase and telophase stages (extruding a pseudo polar 
body) prior to cleavage (fig 1.3).  
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 Fig 1.1 – Schematic diagram of normal fertilisation 
 
 
Fig 1.2 – Schematic of NT using metaphase donor cells with enucleated MII oocyte recipient 
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 Fig 1.3 – Hypothetical schematic of NT using metaphase donor cells with enucleated metaphase 
zygote recipients 
 
Greda, Karasiewicz et al. (2006) used mouse interphase zygotes as recipients for 
NT using blastomeres of various genetic profiles (strains) from 8 cell embryos as 
donors. They employed an alternative enucleation technique when removing the 
pronucleus of the interphase zygotes. This technique allows them to remove the 
nuclear envelope with the attached chromatin, whilst leaving the liquid pronuclear 
contents and nucleoli to remain in the cytoplasm (“selective enucleation”). 
Development of the embryos was then compared between groups where the 
selective enucleation technique was used and those which underwent complete 
enucleation (removal of the entire pronucleus and pronuclear contents). When 
complete enucleation was used no development was observed beyond the four-
cell stage. Using selective enucleation however, development to blastocyst on day 
5 was observed for two strains of blastomeres with an average efficiency of 39%. 
They concluded that cytoplasmic components which are needed for successful 
reprogramming of donor nuclei are incorporated into growing pronuclei, therefore 
removal of these pronuclei would mean removal of the reprogramming 
components which would not allow the embryo to develop correctly (Greda et al., 
2006). 
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Egli, Rosains et al. (2007) considered the theory that factors required for either 
reprogramming or embryonic development in the cytoplasm of oocytes become 
sequestered in the pronuclei of zygotes. They consequently showed that the 
cytoplasm of metaphase-arrested mouse zygotes could support the nuclear 
reprogramming of somatic cells and embryonic stem cells (ESCs) in the mouse. It 
is suggested that the ability of the cytoplasm to reprogram somatic nuclei 
fluctuates with cell cycle, and that one or more factors required for this 
reprogramming localise to the pronuclei during interphase. The fact that embryos 
have now been produced from NT of somatic cells into zygotes of various stages 
shows that reprogramming factors are not lost from the cytoplasm of the oocytes 
following fertilisation (Egli et al., 2007). 
 
The effects on in vitro development using donor cells of various cell cycle stages 
for bovine NT has been previously examined (Tani et al., 2001). Fusing 
metaphase donor cells into MII oocytes resulted in development to blastocyst. NT 
embryos which extruded a second polar body developed to blastocyst at an 
efficiency of 25% and were found to be diploid.  Those embryos which did not 
extrude a second polar body were found to be tetraploid and developed to 
blastocyst at an efficiency of 30%. There was no significant difference in 
development to blastocyst between those embryos which did extrude a second 
polar body, and those which did not. Only those embryos which were diploid (had 
extruded a second polar body) were transferred to recipient cows. Of the five 
embryos transferred, one live calf was produced. It was therefore concluded that 
non-activated oocytes receiving metaphase donor cells have the potential to 
develop into normal calves (Tani et al., 2001). 
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1.3 Candidate reprogramming factors 
 
1.3.1 TCTP 
Translationally Controlled Tumour Protein (TCTP), the gene of which is TPT1, 
has been shown to bind to the microtubules of all mammalian cells during most 
stages of the cell cycle but detaches from the spindle after anaphase and binds 
again at the G1 phase (Gachet et al., 1999). It was discovered that TCTP is 
phosphorylated by the protein kinase Plk, which is the likely cause of TCTP 
detachment from the mitotic spindle (Yarm, 2002). 
 
Koziol, Garrett et al. 2007, found that TCTP activates OCT4 and NANOG 
transcription in transplanted human somatic cell nuclei (Hela cells). Both OCT4 
and NANOG are key pluripotency genes (Boyer et al., 2005). The developmental 
function of TCTP was determined by down regulation of the gene. It was found 
that down regulation of  TPT1 results in significantly reduced OCT4 transcription 
(Koziol et al., 2007). Also, NT experiments have shown that over-expression of 
TPT1 mRNA increases expression of OCT4. These results taken collectively 
suggest that TCTP plays a major role in regulation OCT4 expression. A reduction 
in NANOG transcription was also observed after a down-regulation of TPT1 in 
Xenopus oocytes. It was shown that TCTP binds to the OCT4 promoter but not 
directly to the NANOG promoter, suggesting TCTP regulates OCT4 directly, 
whereas its regulation of NANOG occurs in an indirect way, such as binding to a 
distant site (Koziol et al., 2007). 
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Tani, Shimada et al. (2007) discovered that bovine oocytes which have a high 
ability to reprogram somatic cells contain a phosphorylated protein identified to 
be TCTP. The presence of this protein in oocytes with a high reprogramming 
potential was discovered using 2D polyacrylamide gel electrophoresis (PAGE), 
where a unique spot at the 23 KDa marker was observed. The amino acid 
sequence of this protein was then determined and shown to match the human 
TCTP protein. When enucleated MII oocytes were injected with the 
phosphorylated TCTP protein, their potential to develop to blastocyst was not 
increased, however, it was demonstrated that there was a beneficial effect on in 
vivo development (Tani et al., 2007). 
 
1.3.2 BRG 1 
Hansis, Barreto et al. (2004) developed a protocol to carry out experiments in 
which adult mammalian cells (human 293T kidney cells) are exposed to Xenopus 
egg extract to induce reprogramming. To test for nuclear reprogramming of the 
kidney cells, mRNA expression of OCT4 and GCAP was measured using RT-
PCR. OCT4 and GCAP are pluripotency markers in human and mouse (Matsui et 
al., 1992; Thomson et al., 1998). It was found that in kidney cells exposed to 
Xenopus egg extract, the OCT4 and GCAP pluripotency markers were up 
regulated. An immunodepletion screen was carried out using antibodies to deplete 
chromatin regulators and transcription factors thought to be involved in 
reprogramming. The depletion of the chromatin remodelling ATPase brahma-
related gene 1 (BRG1) consistently inhibited OCT4 up regulation in the 293T 
kidney cells. Competencies of egg extracts of different stages were also tested for 
their ability to up regulate pluripotency markers in the 293T cells. It was found 
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that early blastula (stage 8) Xenopus egg extracts only slightly up regulated OCT4 
and so it was concluded that reprogramming ability of the extract is lost at the 
midblastula transition (MBT). Zygotic transcription in Xenopus embryos is 
initiated during the MBT. This zygotic transcription may activate genes which 
repress pluripotency (Hansis et al., 2004).  
 
Immunocytochemistry of two cell stage mouse embryos shows that BRG1 
dissociates from the chromatin at mitosis (Egli et al., 2008). This makes the 
BRG1 protein an ideal candidate to analyse in my experiments, as mitotic zygotes 
(in metaphase) will be used as recipients in the NT experiments. 
 
1.3.3 HDAC1 
Kim, Liu et al. (2003) suggested that oocytes used as NT recipients repress a 
specific gene expression program by histone deacetylation. HDAC1 is involved in 
the deacetylation of histones and was found to be meiosis specific (localising to 
the chromatin during meiosis but not mitosis) (Kim et al., 2003). 
 
Also, HDAC1 may be associated with the development of a transcriptionally 
repressive state in early mouse embryos (Zeng and Schultz, 2005). Ma and 
Schultz (2008) reported that HDAC1 regulates histone acetylation, development 
and gene expression in pre-implantation mouse embryos. The HDAC1 protein 
was shown to associate with chromosomes at the metaphase I and metaphase II 
stages of the mouse oocyte, and also with the pronucleus of the early zygote. 
Inverse correlations between the immunostaining intensity of histone H4K5 
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acetylation and HDAC1 nuclear staining suggest that HDAC1 is responsible for a 
reduction in the acetylation of histone H4K5. RNAi knockdown of HDAC1 was 
shown to result in hyperacetylation of histone H4K5. This deacetylation of the 
H4K5 histone induces a transcriptionally repressive state in the embryo, as 
deacetylation tends to give a tighter chromatin configuration. The developmental 
ability of HDAC1 depleted embryos is compromised, with significantly smaller 
numbers developing to the blastocyst stage. This may be due to the over 
expression of p21Cip1/Waf, which leads to cell cycle arrest (Ma and Schultz, 2008). 
Epigenetic mechanisms such as histone modifications may play a major role 
during the normal development of the embryo (Fulka, 2008). Fulka (2008) 
examined the role of histone modifications relating to the efficiency of SCNT in 
mouse oocytes, at different stages of maturation and also after the activation of the 
NT reconstructs. Their results indicated that the ability of the oocyte cytoplasm to 
deacetylate the donor cell chromatin disappears soon after activation. Also 
discovered was that that some reprogramming activity appears in the oocyte 
cytoplasm following germinal vesicle breakdown (GVBD) which then disappears 
following activation (Fulka, 2008). This could explain why pre-activated 
cytoplasts (PACs) are unsuitable as recipients for SCNT (Wakayama et al., 2000). 
Using PACs as NT recipients fails to deacetylate the donor chromatin of the 
somatic cell (Wakayama et al., 2000). 
 
By exposing mouse NT embryos to HDAC inhibitors, development can be 
significantly improved. Kishigami, Mizutani et al. (2006) showed in vitro 
development of mouse NT embryos was markedly increased when exposed to 5 – 
50 nM concentrations of TSA for a 10 hour period following activation. 
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Blastocyst development was increased between two and five fold (depending on 
the donor cell type) compared to those NT embryos not exposed to TSA. In vivo 
development of TSA treated embryos was also improved (6% live offspring 
produced) as compared to the control group not treated with TSA (1% live 
offspring produced) (Kishigami et al., 2006). This increase in development may 
be due to reduced DNA hypermethylation or increased histone acetylation in the 
early embryos (Kishigami et al., 2006). 
 
1.4 Aims and objectives 
This study aims to produce blastocysts using metaphase arrested zygotes as 
recipients for NT of metaphase arrested somatic donor cells in bovine. Egli, 
Rosains et al. (2007) produced blastocysts from NT of mitotic somatic cells into 
metaphase arrested mouse zygotes, but did not attempt to generate any live cloned 
offspring. Conditions and procedures for my experiments will need to be 
optimised specifically for bovine. As a control experiment, metaphase arrested 
donor cells will be used for NT into standard MII oocyte recipients. A two-tailed 
Fisher exact test will be used to determine the significance of these results. 
 
As using TII zygotes as NT recipients result in higher in vivo cloning efficiency 
aim to find out about the abundance and localisation of the previously mentioned 
candidate reprogramming factors mentioned in Interphase, Telophase II and 
Metaphase stage bovine zygotes as well as in bovine MII oocytes. Abundance of 
candidate reprogramming factors BRG1 and TPT1 will be measured using reverse 
transcriptase (RT) real-time PCR, following the isolation of mRNA (and 
subsequent conversion to cDNA) from the various samples. Statistical analysis in 
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the form of a two-tailed t-test will be performed on these results to reveal any 
significant differences in the levels of these genes between the different samples.  
 
Localisation of the reprogramming factors in zygotes and cells will be observed 
using immunocytochemistry performed on the various samples. Antibodies will 
be used to stain the samples for the TPT1, BRG1 and HDAC1 proteins, then 
stained with a fluorescent secondary antibody allowing the stain to be viewed 
using fluorescence microscopy. Confocal imaging of the stained samples will also 
be used where necessary. Antibodies will be tested on bovine and human cells 
prior to the staining of the zygote samples, to ensure the antibody will recognise 
the specific antigen in these samples. 
 
 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS
38 
 
2. Methods 
 
2.1 General Methods 
 
2.1.1 Preparation of culture media for bovine cells (DMEM/F12 + 
10%FCS) 
DMEM/F12 base media (89.5 ml) was aliquoted into a measuring cylinder. 500 µl 
Sodium Pyruvate (1mM) and 10 ml FCS were added to the base media. The 
solution was then poured into a beaker and filtered through a 0.2 µm vacucap 
filter into a 250 ml Schott bottle using an aspiration line connected to a vacuum 
pump. Following filtration, the bottle was labelled and placed in a 4°C 
refrigerator. 
 
2.1.2 Thawing cells 
DMEM/F12 + 10% FCS cell media was warmed in a 38°C water bath prior to the 
cells being thawed. The cells were stored in liquid nitrogen and so handling 
required care and speed. A small amount of liquid nitrogen was poured into a 
polystyrene container, the vile of cells placed in the liquid nitrogen and 
transported to the lab. Cells were thawed in a water bath (~38°C) and the vile 
swabbed with ethanol before being placed in a laminar flow hood. 5-10 ml culture 
media was added to a 15 ml conical tube. Once the cell sample was completely 
thawed, the solution was pippetted into the tube containing media (whilst mixing) 
and centrifuged (Biofuge Primo 75005181) at 1000 rpm for 3-5 minutes (this 
centrifuge was used for all cell work). The supernatant was removed using an 
unplugged pipette and the appropriate volume of tissue culture media was added 
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to the pellet. To disperse the cells, the bottom of the tube was tapped lightly on the 
bench. Media and cells were mixed well and transferred to a tissue culture dish. 
The dish was labelled with the date, cell line, passage number and number of 
cells.  Cells were incubated at 38°C until they reached 70-90% confluency. When 
cells were thawed onto cover slips, sterile small round cover slips were placed on 
the bottom of the tissue culture dish before thawing the cells. 
 
2.1.3 Passaging of cells 
Cell culture media (DMEM/F12 + 10% FCS) was aspirated off the cells which 
were then washed with the appropriate volume of PBS (38°C). PBS was aspirated 
off and a small volume of 0.25% trypsin at 38°C (just enough to cover the cells) 
was added to the dish. The cells immersed in trypsin were then incubated in a 
38°C incubator for 3-5 minutes until cells dislodged from the dish. A plugged 
Pasteur pipette was used to aspirate the media and cells up and down to help break 
up any sheets of cells. Cells were then transferred to a conical tube and the 
appropriate volume of culture media added to the tube before mixing thoroughly. 
The tube containing the cells was then centrifuged for 3-5 minutes at 1000 rpm. 
Once the centrifuge had stopped, the tube was remove and the supernatant 
aspirated off and discarded then the pellet loosened by gently tapping the tube. 
Following this, the desired amount of culture media was added to the tube and the 
solution transferred into a tissue culture dish. Cells were incubated at 38°C until 
they were 70-90% confluent. 
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2.1.4 Freezing of cells 
When cells were 70-90% confluent, they were passaged and the total number of 
cells counted using a haemocytometer. Cells were then centrifuged at 1000 rpm 
for 3-5 minutes. The cryo-protectant was made during centrifugation by adding 1 
ml DMSO (drop wise) to 4 ml FCS and filtering. This creates a 20% DMSO 
solution. Freezing media consisted of 50% culture media and 50% cryo-protectant 
solution, giving a final DMSO concentration of 10%. To the pellet of cells, half 
the total volume required in DMEM/F12 + 10% FCS cell culture media was 
added, followed by the remaining volume in cryo-protectant solution (added very 
slowly). This solution was mixed to ensure uniformity and aliquoted into 1 ml 
cryovials on ice. Vials were labelled with the date, passage number, cell ID and 
number of cells then placed in a freezing box in the -80°C freezer. After 24 hours, 
the vials of cells were transferred in to liquid nitrogen. 
 
2.1.5 Aspiration of ovaries 
Ovaries were collected from slaughtered cows on site at the abattoir and removed 
from the reproductive tract using scissors before being placed in warm saline in a 
thermos. The ovaries were then transported back to the lab within 2-4 hours. Prior 
to aspiration, ovaries were removed from the thermos, washed twice in sterile 
0.9% saline (30°C) and stored in a large thermos flask (containing saline). Warm 
aspiration media was placed in sterile 15 ml conical tubes (approximately 2 ml of 
media per tube). The aspiration needle (18 gauge) bung was then placed into the 
tube and a blunt needle pushed through the bung and connected to the aspiration 
line. A negative pressure (approximately -50 mmHg) from the aspiration machine 
was used to generate a vacuum and follicles 3 – 10 mm in diameter were 
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aspirated. Approximately four oocytes per ovary can be expected. Full tubes were 
then searched for oocytes in the embryology lab. 
 
 
Fig 2.1 – Set-up for the aspiration of ovaries 
 
 
2.1.6 In vitro maturation (IVM) 
IVM plates (one per 120 oocytes expected) were prepared at least two hours prior 
to IVM in a laminar flow hood. 12 x 40 µl drops of maturation media with 
cysteamine added were placed into a 6 cm petri dish, using a dropper pipette.  
Drops were then overlaid with 8 ml of gassed mineral oil. Petri dishes were 
labelled with “IVM”, date and user name and equilibrated for a minimum of 2 
hours in a 5% CO2 incubator at 38.5°C.  Ovaries were then aspirated as per the 
ovary aspiration protocol (section 2.1.5). Tubes were placed in a test tube rack and 
the contents allowed to settle. Aspiration media was added to a 9 cm petri dish 
(just enough to cover the bottom of the dish) and a 2 ml syringe with a glass 
Pasteur pipette attached was used to draw up approximately 1 ml of sediment to 
add to the dish containing aspiration media. The dish was placed in a grid plate 
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and the contents searched for cumulus-oocyte complexes (COCs) with a roller 
pipette attached to a glass capillary. Oocytes lacking cumulus cells, or possessing 
a large spotted cumulus were left behind as these oocytes are too mature and this 
can lead to poor development to blastocyst. COCs were transferred to a 3 cm petri 
dish containing H199 + 10% FCS media, then washed in a second 3 cm plate 
containing H199 + 10% FCS.  Oocytes were then washed a third time in a 3 cm 
dish containing B199 + 10% FCS media. From this dish, 10 oocytes in 10 µl of 
the B199 + 10% FCS medium were then transferred to an IVM drop (giving the 
drop a total volume of 50 µl). This was repeated until all selected oocytes were in 
IVM drops. The plate was labelled with the number of oocytes and the time the 
plate was filled before being placed into a 5% CO2, 38.5°C incubator for 22-24 
hours. All work was performed on a warm stage at 38.5°C. 
 
 
Fig 2.2 – Bovine cumulus oocyte complex (From archimede.bibl.ulaval.ca) 
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2.1.7 In vitro Fertilisation (IVF) 
 
2.1.7.1 IVF plate preparation 
IVFSOF (sterile) + 1 µM pyruvate + 1 µM penicillamine + 2 µM hypotaurine + 
10 µg/ml heparin (IVF + PPHH) medium was made up in a laminar flow hood. 
These agents were added to the IVF media to increase the developmental 
efficiency of the zygotes. Pyruvate was added as it is metabolised by the early 
embryo increasing its developmental potential. Heparin was added to capacitate 
the sperm and increase the chances of fertilisation and penicillamine and 
hypotaurine were used to maintain sperm motility. Using a dropper pipette, two 
60 µl wash drops of IVF + PPHH medium were placed at the top of each plate, 
and 12 x 30 µl drops placed throughout the dish (a plate with 12 drops holds up to 
60 oocytes).  The drops were overlaid with 8 ml of sterile warm mineral oil. IVF 
plates and the remainder of the IVF + PPHH medium was placed in a 38.5C, 5% 
CO2 incubator and allowed to equilibrate for at least 2 hours. The cap on the bottle 
of IVF + PPHH medium was loosened to allow pH equilibration during 
incubation. Hepes-buffered synthetic oviduct fluid (HSOF) was also placed in the 
incubator to warm (with the cap tightened). 
 
2.1.7.2 Sperm preparation 
Redigrad™ gradients were prepared in a laminar flow hood by pipetting 
approximately 1.5 ml of 45% Redigrad™ into a 15 ml sterile centrifuge tube, and  
carefully under-laying with 1.5 ml of a 90% Redigrad™ solution. The Redigrad™ 
solution was used for creating a gradient to separate the motile fraction of sperm 
from the semen.  A semen straw (from a standard IVF bull) was selected from the 
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liquid nitrogen tank and thawed for ~ 30 seconds in a 30°C water bath. As a 
general rule, one semen straw (0.25 ml, containing approximately 1 x 108 
spermatozoa/ml) was used to fertilise approximately 150 oocytes. One gradient 
should accommodate two straws of semen. The straw was then dried with tissue 
paper in a laminar flow and wiped with 70% ethanol. To avoid contaminating the 
ends, the straw was handled in the middle from here on. One end of the straw was 
cut off and placed against the inside of the centrifuge tube containing the gradient. 
The other end of the straw was then cut and the sperm allowed to flow into the 
tube and settle on the gradient. Following this, the Redigrad™ gradient and sperm 
was centrifuged (Biofuge primo 75005181 centrifuge) at 700 g for at least 20 
minutes. Sperm was recovered as soon as the centrifuge stopped to prevent motile 
sperm swimming up the gradient. Using a sterile glass Pasteur pipette and syringe, 
the sperm pellet was removed from the bottom of the tube and re-suspended in 1 
ml HSOF medium. This was then centrifuged (Biofuge primo 75005181 
centrifuge) at 200 g for 5 minutes. While this centrifugation was in progress, 190 
µl of water was pipetted into a glass tube. Immediately after the centrifuge had 
stopped, the supernatant was removed and the sperm pellet resuspended in 200 µl 
of equilibrated IVF + PPHH medium. This was mixed gently and a 10 µl aliquot 
of the solution was added to the 190µl of water (a 1:20 dilution). The remaining 
volume of sperm solution was measured in the tube using a Pasteur pipette 
attached to a 1 ml syringe. While calculating sperm concentration, the solution 
was placed in a dark place, as U.V light is damaging to the sperm DNA. 
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2.1.7.3 Calculating sperm concentration 
Cover glass was placed over the support shoulders of a haemocytometer. 10 µl of 
the 1 in 20 sperm dilution (from the glass tube) was pipetted against the edge of 
the cover glass until the grid was filled. Both sides of the haemocytometer were 
filled while taking care not to overfill. Sperm was counted in the 25 large squares 
that make up the grid on the haemocytometer (both sides). The following formula 
was used to get a final concentration of 1 million sperm/ml: 
Volume measured (A) x average number of sperm count (B) = Total volume (C) 
    25 
Total volume (C) – volume measured (A) = volume of IVF + PPHH medium to 
add to the sample (D). Volume (D) was added slowly so that the sperm did not 
suffer dilution shock. 10 µl of the diluted sperm sample was added to each 40 µl 
drop containing oocytes in the IVF plates. Sperm were checked to ensure they 
were motile. The plates were placed in a 5% CO2 incubator for 6 hours. After 6 
hours, zygotes were stripped (cumulus cells removed) in HSOF + 0.1% 
hyaluronidase (an enzyme which digests the cumulus cells) and placed in group 
culture IVC plates. 
 
2.1.8 Removal of cumulus from metaphase II oocytes 
Two 3 cm petri dishes containing H199 + 10% FCS, and a third 3 cm dish with 
H199 + 3 mg/ml BSA were poured. The dish containing H199 + 3 mg/ml BSA 
was labelled “3”, and the dishes containing H199 + 10% were labelled “1” and 
“2”. Oocytes were removed from IVM and placed into the dish labelled “1”. 
Then, taking as little media as possible, the oocytes were transferred to an 
eppendorf tube containing a 500 µl aliquot of 0.1% Hyaluronidase in H199.  This 
was then vortexed for three minutes at 2200 rpm and spun down for a few seconds 
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in a Labnet Spectrafuge mini C1310 (2000 g maximum speed). Using a 200 µl 
pipette, all liquid along with the pellet of oocytes was removed from the tube and 
placed back into the first wash dish. Oocytes were swirled into the middle of the 
dish and transferred to the second wash dish (labelled “2”). The oocytes were 
washed again by swirling the dish and transferred to the third dish containing 
H199 + 3 mg/ml BSA. A mouth pipette was used to search oocytes for the 
presence of a polar body. In the dish, the oocytes were separated into two groups; 
those with a polar body and those without. Those with a polar body (extruded set 
of chromosomes to produce a haploid oocyte) were classed as being in the 
“Metaphase II” stage and were used for nuclear transfer (NT). Oocytes without a 
polar body were discarded. If the oocytes were to be zona-free, they were 
incubated in a drop of pronase (5 mg/ml dissolved in Ca and Mg free PBS) until 
the zona-pellucida disappeared, then washed out of the pronase in H199 + 10% 
FCS. 
 
2.1.9 Removal of cumulus from IVF zygotes 
Zygotes were removed from IVF and placed in a 3 cm petri dish containing 
HSOF. The zygotes were then taken from the dish using a pipette (carrying over 
minimal media so as not to dilute the hyaluronidase) and placed in an eppendorf 
tube containing 0.1% hyaluronidase in HSOF. Following this, the tube containing 
the zygotes was vortexed for two minutes at 2000 rpm and spun down using a 
mini centrifuge (Labnet Spectrafuge C1301) for a few seconds. After vortexing, 
the entire content of the tube was removed using a 200 µl pipette and expelled 
into a second 3 cm petri dish containing HSOF. Embryos with cumulus cells 
removed were washed through a third dish containing HSOF before being placed 
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into IVC. Zygotes were then placed in a drop of pronase (5 mg/ml dissolved in Ca 
and Mg free PBS) until the zona-pellucida disappeared (observed under a 
microscope) before placing in IVC (if zona-free zygotes were required). 
 
2.1.10 Nuclear transfer (NT) procedure 
NT plates were made the previous day and held in the fridge overnight. Plates 
included: Hold plates (for holding the zygotes and oocytes before enucleation), a 
stain plate with 5 µg/ml Hoechst 33342 (Invitrogen, NZ), a cytoplast plate (for 
holding enucleated zygotes and MII oocytes), a lectin (200 µg/ml in H199 + 3 
mg/ml BSA) plate for sticking cells to the cytoplasts, and a post-fusion plate for 
holding the fused NT reconstructs. All plates were made by placing 30 µl drops in 
a 6 cm petri dish and overlaying with 8 ml mineral oil. Chromosomes of 
recipients (MII oocytes or metaphase zygotes) were stained with 5 µg/ml Hoechst 
33342 in H199 for approximately 5 minutes prior to enucleation. Enucleation was 
carried out using a blunt aspiration pipette (25–30 µm in outer diameter) and 
separation needle (100-150 µm in outer diameter) with a closed fire-polished tip. 
No holding pipette was used as the recipients were zona-free. Oocytes and 
zygotes were then enucleated in a drop of H199 + 3 mg/ml BSA under oil at 100 
× total magnification.  All tools were made from thin wall borosilicate capillaries 
(CG100T-15, Harvard Apparatus Ltd., UK) using a horizontal puller (P-87, Sutter 
Instruments, CA) and a microforge (MP-9, Narishige, Japan) (Oback and Wells, 
2003). Mitotic nuclei were removed from zygotes and metaphase II (MII) oocytes 
(those which have extruded a polar body). The MII oocyte group was used as a 
control. Cytoplasts were stuck to metaphase arrested donor cells (cell line LJ801 ~ 
passage 5) in H199 + 3 mg/ml BSA containing lectin. Couplets were then 
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electrically fused, using two pulses of 450 V with a 30 µs pulse length in a 
parallel plate fusion chamber filled with 205 osm fusion buffer. Fused couplets 
(where the donor cell has moved inside the oocyte) were placed into a post-fusion 
plate before activation. 
 
2.1.11 Activation of fused reconstructs 
Cycloheximide (CHX) plates were made the morning before activation and placed 
in a CO2 gassed incubator. Each CHX plate consisted of a 6 cm Petri Dish 
containing three 40 µl wash drops at the top of the plate and 35 x 5 µl drops 
throughout the plate overlaid with 8 ml of mineral oil. The concentration of CHX 
used was 10 µg/ml (diluted in ESOF medium). Immediately after fusion had been 
scored (for the metaphase NT experiments), fused reconstructs were placed in a 
3cm petri dish containing HSOF + 1 mg/ml BSA for approximately 15 minutes. 5 
ml of a 5 µM ionomycin solution in HSOF + 1 mg/ml BSA was made up and 
placed in a 3 cm petri dish. Ionomycin was used as it is a calcium ionophore, 
allowing an influx of Ca2+ into the oocyte to mimic the process of normal 
fertilisation. Reconstructs were activated by being placed in the ionomycin 
solution for exactly 4.5 minutes before immediately transferring them to a 3 cm 
petri dish containing HSOF + 30 mg/ml BSA media where they were left for at 
least three minutes. The embryos were then washed three times in the wash drops 
of CHX plates and individually placed in the 5 µl drops. CHX was used for 
activation as it allows for extrusion of the second polar body, another activating 
agent commonly used; 6-dimethylaminopyridine (6-DMAP) does not. After six 
hours in CHX, the reconstructs were washed out of the cycloheximide and 
transferred to IVC. 
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2.1.12 In vitro culture (IVC) 
All plates for IVC were prepared in a laminar flow hood. For group culture plates 
(zona-intact embryos) a 3 cm petri dish was used. Using a dropper pipette, two 
central wash drops of 40 µl size were placed into the petri dish and surrounded by 
six 20 µl drops of Early Synthetic Oviduct Fluid (ESOF) medium. The drops were 
overlaid with 3 ml of mineral oil. Plates were then placed in a modular incubator 
chamber with a small amount of milli-Q water in the base. The O-ring 
surrounding the lid of the chamber was greased with a small amount of lubricant, 
and the modular incubator chamber gassed for 5 minutes with 5% CO2, 7% O2, 
and 88% N2 to allow the plates to equilibrate (for at least two hours). Following 
this, the chamber with the plates was then placed in a “dry” (non-gassed) 38.5°C 
incubator. A plate of B199 + 10% FCS was placed into the chamber as an 
indicator (this should always remain a salmon pink colour) to ensure the chamber 
remains gassed.  Using a mouth pipette, the zygotes were washed through both the 
central wash drops of the IVC plates, and 10-15 zygotes placed in each of the six 
20 µl drops in the plate. Plates remaining in the incubator chamber continued to 
be gassed whilst working with other plates. On day 5, embryos were changed over 
to fresh drops of Late Synthetic Oviduct Fluid (LSOF) medium. LSOF plates 
were made the same way as the ESOF plates, and also equilibrated for at least two 
hours in a gassed modular incubator chamber. On day 5 during the change over, 
cleavage (embryos which have progressed passed the one cell stage) and the 
number of tight morulae (TM)/compacted morulae were recorded. During day 7, 
embryos were graded for blastocyst development (appendix A: Criteria for 
grading of bovine blastocysts). 
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For the single culture of zona-free zygotes, the same fundamental protocol 
applies, however plates were made differently. 6 cm petri dishes were used, with 
three 40 µl wash drops of ESOF/LSOF medium at the top of the plate. 30 x 5 µl 
drops of ESOF/LSOF medium were then placed in rows throughout the plate 
(three rows of eight drops, and the final row of six drops). The drops were then 
overlaid with 8 ml of mineral oil. 
 
2.1.13 Isolation of mRNA 
All steps of this procedure were carried out on ice. The appropriate volume of 
trizol was added to a cell sample or embryo sample. 1 µl ms2 RNA (200 ng/µl) 
and 5 µl alpha globin (1 pg/µl) was then added to the sample. Ms2 RNA 
preferentially sticks to the sides on the PCR tube to prevent any loss of RNA from 
the sample. Alpha globin spikes the sample with a known amount of a specific 
RNA. Samples were then mixed by pipetting and spun in a mini centrifuge 
(Eppendorf minispin plus 5453) for a few seconds. The appropriate volume of 
chloroform was added (to give a 1:5 ratio) and again mixed by pipetting. This was 
then spun at 5000 g (Biofuge fresco 75005521 centrifuge) at 4°C for 10 minutes 
and the upper aqueous phase removed then transferred to a new tube. 2 µl linear 
acrylamide (5 µg/ml) was then added, this aids in the sterilisation of the 
precipitate. An equal volume of isopropanol (~50 µl) was also added then the 
solution mixed briefly using a vortex. The samples were then incubated for 10 
minutes at room temperature, spun at 14000 rpm for 30 minutes at 4°C (Biofuge 
fresco 75005521 centrifuge), with care taken to ensure tubes were orientated 
correctly so the small pellet was not lost. Following centrifugation, the 
supernatant was decanted and the pellet washed with ~70 µl of 70% ethanol then 
51 
 
spun again (Biofuge fresco 75005521 centrifuge) at 14000 rpm for 10 minutes 
(tubes orientated correctly). The resulting supernatant was again decanted and the 
pellet allowed to air dry. Once dry, the pellet was resuspended in 8 µl of DEPC 
water, centrifuged (Eppendorf Minispin plus 5453) for a few seconds then 
incubated for 5 minutes at 65°C before being placed on ice for 30 minutes. 
 
DNase treatment involved adding 1 µl of 10X DNase buffer (Invitrogen, NZ) and 
1 µl of DNase (Invitrogen, NZ). Samples were then spun down and incubated at 
37°C for 60 minutes. 1 µl EDTA (25mM, Invitrogen, NZ) was added, and the 
samples were spun down again and incubated for 10 minutes at 65°C. 1.5 µl 
Sodium Acetate along with 45 µl 100% ethanol was then added and left at -80°C 
for 1 hour or -20°C overnight. After freezing, the samples were spun at 14000 rpm 
for 30 minutes (4°C) with tubes orientated correctly. The supernatant was then 
aspirated off, the pellet washed in 70% ethanol and spun at 13000 rpm (4°C) for a 
further 10 minutes. Ethanol was removed and the pellet allowed to air dry. The 
pellet was then resuspended in 11 µl of DEPC water, spun down and redissolved 
by incubating at 90°C for 2 minutes. Samples were left on ice for 2 minutes before 
beginning the cDNA synthesis. 
 
1 µl dNTP mix (10mM, Invitrogen, NZ) was added to the 11 µl RNA sample 
along with 1 µl of random hexamers (Invitrogen, NZ) and this was incubated at 
65°C for 5 minutes. Samples were then left on ice for 1 minute following the 
incubation and spun down in the mini centrifuge (Eppendorf Minispin plus 5453). 
10 µl of master mix (2 µl 10X First strand buffer, 4 µl MgCl2 (25mM), 2 µl DTT, 
1 µl RNase OUT, and 1 µl Superscript III – not added to no RT control. All 
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Invitrogen, NZ) was added to each RNA sample. Once the master mix was added, 
samples were vortexed and incubated for 10 minutes at 25°C, 50 minutes at 50°C 
and finally 5 minutes at 85°C before being placed on ice. 1 µl of RNase H 
(Invitrogen, NZ) was then added and the samples incubated for 20 minutes at 
37°C.  Following RNase treatment, cDNA samples were stored at -80°C.  The no 
RT control is a sample of mRNA that has not been transcribed to cDNA, and so 
should not be amplified in the PCR. This control was used as an indicator of any 
nuclear DNA contamination. 
 
2.1.14 Real-time PCR 
All pipettes and the work space were wiped with ethanol before use, and gloves 
worn at all times during this procedure. Roche LightCycler® Master Mix 
(LCMM) was made by adding 14 µl of the Roche LightCycler® enzyme mix 
(tube labelled 1a) to the Roche LightCycler® reaction mix (tube labelled 1b). 
 
Samples were thawed, vortexed and centrifuged briefly (Eppendorf minispin plus 
5453) before use. For each run, an RT –ve control and NTC (no template control, 
containing only DEPC water instead of cDNA) were included in the analysis. A 
master mix containing 0.4 µl of each primer (forward and reverse), 2 µl LCMM 
and 5.2 µl of water was made for each gene to be analysed. Note that the volumes 
used are per sample i.e. – if 10 samples were to be run, 10 times the volumes was 
used. 
All primers used for PCR analyses were obtained from Invitrogen NZ Ltd. 
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8 µl of the master mix was added to each capillary along with 2 µl of the cDNA 
template, making total volume per capillary 10 µl. The maximum number of 
samples one can run on a LightCycler® is 32. 
Capillaries were loaded into the Roche LightCycler® carousel by vertically 
dropping each capillary into the appropriately numbered well. Once all capillaries 
were loaded, each one was pushed down using straight vertical pressure until it 
locked into place. 
 
Samples were spun down in a Roche LightCycler® carousel 2.0 centrifuge. The 
carousel containing the samples was placed into the rotor and the rotor placed into 
the centrifuge with the Roche symbol facing upwards. Capillaries were then spun 
in the centrifuge at 15000 rpm for 15 seconds. Once finished, the carousel was 
removed from the rotor and placed into the LightCycler® machine (locking the 
rotor into place). LightCycler® software was used to start a new experiment. A 
self-test was performed prior to carrying out the run if the machine had not been 
used previously that day. Run conditions for the experiment were specified, as 
was the number of samples. The run was started and samples named appropriately 
in the software. In some cases, capillaries were frozen at -20°C following the run 
in order to load the samples on to a gel in future. 
 
2.1.15 Immunocytochemistry of cells 
The cell line used for immunocytochemistry (ICC) was passaged onto a 3 cm 
tissue culture petri dish, containing ~ 6 small round cover slips. Once the cells 
were 70 - 90% confluent, they were fixed in a 4% paraformaldehyde (PFA) 
solution at 4°C for 30 minutes. After the cells were fixed, they were washed twice 
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in phosphate-buffered saline (PBS) and then placed in a 50 mM solution of NH4Cl 
for 10 minutes. This improves the specificity of the staining. The cells were then 
permeabilised in a 0.1% Triton X-100 solution for 10 minutes. Cells (on cover 
slips) were washed out of TX-100 3 times in PBS, then left in blocking buffer (3% 
BSA dissolved in Milli-Q Water) at 4°C for 30 minutes. Cover slips were then 
removed from blocking buffer and placed in the primary antibody solution 
(diluted in blocking buffer).  This was achieved by placing them face down onto 
20 µl drops of the primary antibody on Parafilm™ laid on damp filter paper inside 
a wet chamber. The wet chamber was sealed around the edges with Parafilm™ 
and placed in the fridge overnight. Cells were washed out of the primary antibody 
by washing 3 times in PBS.  Following washing, the cover slips were placed in 
the secondary antibody solution in blocking buffer, also containing Hoechst 
33342 dye in another wet chamber and incubated at 37°C for 30 minutes. Cells 
were then washed out of the secondary antibody by washing 3 times in PBS and 
once in Milli-Q water before being mounted on slides in 5 µl of DAKO™ 
mounting medium. Slides were placed in fridge and sealed with nail polish. Slides 
were viewed under fluorescence using an Olympus BX-50 microscope with 
attached mercury lamp and camera. 
 
2.1.16 Immunocytochemistry of oocytes and embryos 
Oocytes/embryos were fixed in a 4% paraformaldehyde (PFA) solution at 4°C for 
30 minutes. Once fixed, they were washed twice in 0.1 mg/ml PBS/PVA and 
placed in a 50 mM solution of NH4Cl for 10 minutes to improve the specificity of 
the staining.  Fixing and washing steps were done in 30 µl drops in a 6 cm petri 
dish overlaid with 8 ml of mineral oil. Quenching in 50mM NH4Cl was carried 
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out in 30 µl drops in a 6 cm dish also containing 30 µl drops of blocking buffer, 
overlaid with mineral oil. Following quenching in NH4Cl, oocytes/embryos were 
permeabilised in the 0.1% TX-100 solution in a 3 cm petri dish for 10 minutes. 
Permeabilised samples were washed once in a 3cm petri dish of PBS/PVA (0.1 
mg/ml) before being placed in drops of the blocking buffer in a 6 cm petri dish. 
The oocytes/embryos were left in the blocking buffer for 30 minutes at room 
temperature then placed in the fridge for a further 60 minutes. After removal from 
the blocking buffer samples were then incubated in the primary antibody (diluted 
to the appropriate concentration in blocking buffer) overnight in a refrigerator.  As 
a negative control some oocytes/embryos were incubated only in blocking buffer 
(not containing the primary antibody). The following morning, the 
oocytes/embryos were washed out of the primary antibody three times in 
PBS/PVA then incubated with the secondary antibody/Hoechst 33342 (5 µg/ml) 
for 30 minutes at 37°C. Finally, after removal from the secondary antibody, they 
were washed three times in PBS/PVA and once in milli-Q water before being 
mounted in 5 µl of DAKO™ mounting medium under a cover slip and sealed with 
nail polish. Double staining was carried out on embryos by incubation in two 
primary antibodies diluted in blocking buffer followed by incubation in the two 
appropriate secondary antibodies. Slides were viewed under fluorescence using an 
Olympus BX-50 microscope with attached mercury lamp and camera. Confocal 
imaging of embryos was carried out using an Olympus FluoView FV1000 
confocal microscope. 
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2.1.17 Statistical analysis 
Statistical analysis was carried out using Microsoft Excel®. A two-tailed t-test 
was used for the real-time RT PCR results, with the assumption that the samples 
have unequal variances. This statistical analysis reveals if there are any significant 
differences between the concentrations of the target genes in the various samples 
relative to 18S, and also between the “MII Equivalents” of the samples. The 
accepted level of significance was P < 0.05. 
 
For the statistical analysis of developmental data, a two-tailed Fisher Exact test 
was used to determine the significance of results i.e. – if the developmental results 
(to blastocyst) of two groups differ significantly.  The accepted level of 
significance was again P < 0.05. 
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2.2 Metaphase Zygote NT Methods 
 
2.2.1 Metaphase zygote NT procedure 
The morning of NT at approximately 8:30am, zygotes were moved from ESOF 
medium to ESOF + nocodazole medium (0.5 µg/ml nocodazole concentration). 
Zygotes were retained in the ESOF + nocodazole medium for 4.5 hours. When 
enucleation was due to be commenced, the zygotes were removed from the ESOF 
+ nocodazole medium and incubated in pronase to remove the zona pellucida. 
Any 2-cell embryos were discarded at this stage. Zygotes were then placed in 
drops of H199 + 3mg/ml BSA + nocodazole. All media from this point on 
contained nocodazole at a concentration of 0.5 µg/ml, to prevent zygotes or donor 
cells exiting mitosis during the NT procedure. The zygotes were then stained with 
Hoechst 33342 dye (5 µg/ml) for approximately 5 minutes prior to enucleation. 
Zygotes were selected on the microscope stage during enucleation for metaphase 
chromosomes (Fig 2.3) and enucleated under U.V illumination. Successfully 
enucleated metaphase zygotes (zygotic cytoplasts) were held in drops of H199 + 
3mg/ml BSA – nocodazole. The cytoplasts were then stuck to metaphase donor 
cells using lectin (200 µg/ml) before being fused to the metaphase arrested donor 
cells and placed into IVC. The basic procedure for these experiments is shown in 
fig 2.4. 
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 Fig 2.3 – Zygote arrested in metaphase showing condensed chromosomes 
 
IVF 
6 hpf
IVCIVM
20.5 hours 22.5 hpf
ESOF + Nocodazole
4.5 hours
Enucleation
Sticking Fusion
IVC
Metaphase Zygote NT Procedure
 
Fig 2.4 – Basic schematic of metaphase zygote NT experiment 
 
2.2.2 Control NT experiments using MII oocyte recipients 
Control NT experiments using MII oocytes as recipients of metaphase donor cells 
were carried out using the standard NT procedure as described in section 2.1.10. 
However, couplets (enucleated MII oocyte stuck to a metaphase donor) were kept 
in media containing nocodazole from the point they were stuck to the metaphase 
arrested donor cell in lectin. This prevents the donor cell from exiting mitosis 
during the NT procedure (fig 2.5). 
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IVM
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Enucleation Sticking
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Control NT Procedure
 
Fig 2.5 – Basic schematic of control NT experiments 
 
2.2.3 Metaphase arrest of somatic donor cells 
LJ801 (approximately passage 5) cells were thawed into three wells of a four well 
plate. The cells were seeded at a density of 5 x 104 cells per well in 1ml 
DMEM/F12 + 10% FCS media, and left to grow overnight. Prior to NT, cells 
were treated with nocodazole (0.5 µg/ml) by adding nocodazole to the media in 
the wells. The cells were then incubated for two hours at 38.5°C. Following this, 
the plate was tapped to dislodge the metaphase arrested cells and the media and 
cells were centrifuged (Biofuge primo 75005181) then the cell pellet resuspended 
in 250 µl H199 + 0.5% FCS + nocodazole. 40µl drops of the cells in H199 + 0.5% 
FCS + nocodazole were then on a 3cm petri dish and overlaid with mineral oil 
before selection of the cells for NT. Cells were assessed as being in metaphase by 
morphology and clarity. Only large, round, transparent donor cells were classed as 
metaphase and used as donors for the NT experiments.  
 
2.2.4 Chromatin analysis of early embryos 
Embryos at time points of pre fusion (couplets), immediately post fusion, two 
hours post fusion (hpf), four hpf, 19 hpf and 24 hpf were fixed in 4% 
Paraformadehyde (PFA) for 30 minutes at 4°C. The embryos were then stained 
with Hoechst 33342 dye and the distribution of chromatin analysed by exposure 
of the stained embryos to U.V light. 
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2.2.5 Cytochalasin B (CB) treatment of embryos 
IVC was carried out on the embryos/NT embryos according to the procedure 
described in section 2.1.12. The ESOF medium used for the IVC contained CB 
(7.5 µg/ml) to prevent cleavage of embryos. Embryos were kept in the ESOF 
medium + CB for periods of either four or 17 hours, after which time they were 
washed out in ESOF medium not containing CB for approximately 30 minutes 
and allowed to cleave. Embryos which did not cleave were discarded. Once 
cleaved, the embryos were placed into IVC, or fixed in 4% PFA for 30 minutes at 
4°C. The embryos fixed in 4% PFA were stained with Hoechst 33342 and viewed 
under U.V for analysis of their chromatin distribution. Embryos placed into IVC 
were cultured to day 7 and their development to blastocyst was assessed. A 
control group containing embryos in ESOF - CB (ESOF + 1.5 µl/ml DMSO) was 
also present in these experiments. 
 
2.2.6 Nocodazole washout treatment of metaphase zygote NT 
embryos   
Before metaphase zygote NT embryos were placed into IVC, they were washed 
out of nocodazole containing media in H199 + 3mg/ml BSA – nocodazole for 
periods of either 30 minutes (group 1) or 60 minutes (group 2). Following their 
washout they were placed into IVC as according to the procedure in section 
2.1.12. 
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2.3 mRNA Analysis Methods 
 
2.3.1 Interpretation of Real-time PCR results 
All real-time PCR reactions were carried out on a Roche LightCycler® system 
using the LightCycler® FastStart DNA Master Plus SYBR Green I kit. 
Real-time PCR amplifies DNA (or cDNA) and can quantify it by attaching a 
fluorescent probe (in this case SYBR green) to the DNA and measuring the 
fluorescence intensity (Valasek and Repa, 2005).  The PCR reaction only 
amplifies DNA up to a certain threshold efficiently, before a plateau phase is 
reached. Real-time PCR measures DNA amplification efficiently in the 
exponential phase (the steep part of the amplification curve where the product 
increases exponentially) (Valasek and Repa, 2005). The point where the product 
begins to amplify exponentially is termed the crossing-point (or Cp value). 
Dissociation or “melting” curves produced at the end of the PCR run show 
whether a specific PCR product was created. These should show a single sharp 
peak at a specific temperature for the product which differs from the melting 
points shown for the NTC and RT –ve controls (Valasek and Repa, 2005). An 
example of a real-time PCR output is shown in figures 3.4 and 3.5. 
 
2.3.2 Standard curve derivation 
To generate a standard curve, a known amount of cDNA was used as the starting 
material. Dilutions were done in 1/10 amounts as the concentrations covered the 
same range of Cp’s as the samples. An example of dilutions performed for 
deriving a standard curve is shown in table 2.1. 
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Table 2.1 – Example of standard curve dilutions 
Conc. Dilution Sample 
Amount 
Water or TE 
Amount 
Total Volume 
(µl) 
1 1 2µl 0 2 
0.1 1/10 1µl 9µl 10 
0.01 1/100 1µl of 1/10 9µl 10 
0.001 1/1000 1µl of 1/100 9µl 10 
0.0001 1/10000 1µl of 1/1000 9µl 10 
  
Before being added to the capillary, each sample was vortexed and spun down in 
the mini centrifuge (Eppendorf minispin plus 5453) then loaded into the 
capillaries as per the Real-time PCR protocol in the section 2.1.14. Each sample 
was done in duplicate. Once the run was complete, the melting curve analysis was 
checked to ensure the No Template Control (NTC) had a different melting peak 
from the samples. Absolute quantification analysis was done using the 
LightCycler® software, with “standard” selected as the sample type and the 
sample concentration specified to produce the standard curve. The standard curves 
were then exported into the Excel program and a scatter plot produced fitted with 
a logarithmic regression. Using the regression equation and the formula 
[concentration] = e(-(Cp-intercept)/slope), Cp values were able to be converted to a 
relative concentration. 
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2.3.3 Quantification of gene expression 
Absolute gene expression values were gained by converting Cp values to an 
absolute concentration (in relative units) using the equation gained from the 
standard curve graph. Relative gene expression was calculated by dividing the 
absolute concentration of the target gene by the concentration of the house-
keeping gene (18S) in the samples. 18S was used as the normalising or house-
keeping gene in these experiments. The quantity of 18S is not expected to change 
under the experimental conditions and can therefore act as an internal standard 
(Valasek and Repa, 2005). However it has been discovered that levels of house-
keeping genes may be highly variable (Dheda et al., 2004), and this may affect the 
results. 
 
2.3.4 18S mRNA analysis 
All real-time PCR analysis for 18S was carried out according to the real-time RT-
PCR method (section 2.1.14). The primers for 18S were: 
Forward Primer: GAC TCA TGG CCC TGT AAT TGG AAT GAG GC 
Reverse Primer: GCT GCT GGC AAC AGA CTT G 
Annealing temperature: 56°C 
Fragment size: 87bp 
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2.3.5 TPT1 mRNA analysis 
All real-time PCR analysis for TPT1 was carried out according to the real-time 
RT-PCR method (section 2.1.14). The primers for TPT1 were: 
Forward Primer: TCT ACA AGA TCC GGG AGA TCG 
Reverse Primer: GAC ACC AGT GAT TAC TGT GCT 
Annealing temperature: 60°C 
Fragment size: 161 bp 
 
2.3.6 BRG1 mRNA analysis 
All real-time PCR analysis for BRG1 was carried out according to the real-time 
RT-PCR method (section 2.1.14). The primers for BRG1 were: 
Forward Primer: GAC AAG CGC CTG GCC TA 
Reverse Primer: ACC AGC TCC GTG AGG TTA 
Annealing Temperature: 60°C 
Fragment Size: 165 bp 
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2.4 ICC Methods 
 
2.4.1 Selection of zygotes 
Zygotes were generated using the standard IVF procedure (section 2.1.7) and 
stripped of cumulus cells. The zygotes were then incubated in pronase until zona-
free and stained in H199 + 3 mg/ml BSA + Hoechst 33342 dye (5 µg/ml). 
Telophase II zygotes were selected under U.V fluorescence (to observe telophase 
nuclei) at 4.5 hpf (hours post fertilisation). Interphase zygotes were selected under 
U.V fluorescence 22.5 hpf, and metaphase zygotes selected under U.V 
fluorescence at 27 hpf (after 4 hours in ESOF + 0.5 µg/ml nocodazole). 
 
2.4.2 TCTP ICC of somatic cells, oocytes and zygotes 
All ICC carried out on cells, oocytes and zygotes using the TCTP antibody, was 
done so according to the procedures in sections 2.1.15 and 2.1.16. The TCTP 
antibody (MBL, Japan) was used at a concentration of 1:1000. This concentration 
was found to be optimal after trialling the antibody at concentrations of 1:250, 
1:500 and 1:1000. The secondary antibody was the anti-rabbit Alexa-Fluor 568 
(Molecular Probes, Invitrogen, NZ), used at a concentration of 1:1000. When 
double staining of zygotes using the TCTP and lamin (nuclear proteins, to see if 
TCTP associates with nuclear material) antibodies was carried out, the lamin 
antibody was used at a concentration of 1:100. The secondary antibody used for 
lamin was anti-goat rhodamine (Jackson ImmunoResearch Inc. PA, USA) which 
was used at a concentration of 1:300. The secondary antibody used for TCTP in 
the double-staining experiments was anti-rabbit Cy2 (Jackson ImmunoResearch 
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Inc. PA, USA). Samples were also stained with Hoechst 33342 dye in order to 
visualise the nuclear DNA. 
 
2.4.3 BRG1 ICC of somatic cells and zygotes 
All ICC carried out on cells using the BRG1 antibody (Santa Cruz, CA, USA) was 
done so according to the procedures in sections 2.1.15 and 2.1.16. The primary 
antibody (BRG1) was used at a concentration of 1:50 (the strongest concentration 
recommended by the manufacturer). The secondary antibody used in these 
experiments was anti-goat rhodamine (Jackson ImmunoResearch Inc. PA, USA), 
which was used at a concentration of 1:300. Samples were also stained with 
Hoechst 33342 dye in order to visualise the chromosomes. 
 
2.4.4 HDAC1 ICC of somatic cells, oocytes and zygotes 
All ICC carried out on cells, oocytes and zygotes using the HDAC1 antibody 
(Millipore, MA, USA), was done so according to the procedures in sections 2.1.15 
and 2.1.16. The HDAC1 primary antibody was used at a concentration of 1:250. 
This concentration was found to be optimal, when concentrations of 1:250, 1:500 
and 1:1000 were tested. The secondary antibody for these experiments was the 
anti-rabbit Alexa-Fluor 568 (Molecular Probes, Invitrogen, NZ), used at a 
concentration of 1:1000. 
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2.5 Reagents, solutions and media composition 
 
M199 
Medium 199 containing Earle’s salts and L-glutamine, but no NaHCO3 (Life 
Technologies; cat. no. 31100-035) 
 
B199 
Bicarbonate buffered medium M199 with 25mM NaHCO3 and 0.086 mM 
kanamycin monosulfate 
 
IVM medium 
B199 + 10% FCS with 10 µg/ml ovine follicle-stimulating hormone (FSH) 
(Ovagen; Immuno-Chemical Products [ICP], Auckland, New Zealand), 1 µg/ml 
ovine luteinising hormone (LH) (ICP), 1 µg/ml 17-β-estradiol and 0.1 mM 
cysteamine for in vitro maturation (de Matos et. al. 1995). 
 
HSOF 
Hepes-buffered synthetic oviduct fluid (SOF) with 107.7 mM NaCl, 7.15 mM 
KCl, 0.3 mM KH2PO4, 5 mM NaHCO3, 3.32 mM sodium lactate, 0.069 mM 
kanamycin monosulfate, 20 mM Hepes, 0.33 mM pyruvate, 1.71 mM CaCl2.2H20, 
3 mg/ml fatty-acid free bovine albumin (ABIVP;ICP) (Thompson et. al. 1990). 
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Aspiration media 
H199 + 925 IU/ml Heparin (CP Pharmaceuticals Ltd., UK) + 20% (w/v) Albumin 
concentrate (ICP). 
 
IVF SOF medium 
107.7 mM NaCl, 7.15 mM KCl, 0.3 mM KH2PO4, 25 mM NaHCO3, 3.32 mM 
sodium lactate, 1.71 mM CaCl2.2H20, 0.04 mM kanamycin monosulfate, 8 mg/ml 
fatty-acid free bovine albumin (ABIVP, ICPbio), supplemented with 0.33 mM 
sodium pyruvate, 0.001 mM Heparin, 0.2 mM penicillamine and 0.1 mM 
hypotaurine. 
 
RedigradTM
Composition: Silica sol with covalently linked saline 
Density (g/ml): 1.130 ± 0.005 
Osmolarity (mOsm/kg H20): max. 30 
Viscosity (cP): max. 15 at 20°C 
pH: 9.4 ± 0.5 at 20°C to 25°C 
Endotoxin (EU/ml): max. 2 
GE Healthcare Life Sciences, Level 1, 8 Tangihua Street, Auckland 1010, New 
Zealand. 
 
Biphasic AgR SOF (ESOF) 
Biphasic AgResearch Synthetic Oviduct Fluid medium (AgR SOF, AgResearch, 
Hamilton, New Zealand). AgR SOF is a modified formulation to that used by 
Gardner et al., (1994) containing 8 mg/ml BSA (Wells et. al. 2003). 
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Biphasic AgR SOF (LSOF) 
LSOF is the biphasic AgR SOF (ESOF) medium, containing 10 µM 2,4-
dinitrophenol which acts as an uncoupler of oxidative phosphorylation (Wells et. 
al. 2003).  
 
Fusion buffer (205osm) 
200 mM mannitol, 50 µM CaCl2, 100 µM MgCl2, 500 µM Hepes, 0.05% bovine 
albumin (ABIVP, ICP), pH 7.3 (Oback and Wells, 2003). 
 
4% Paraformaldehyde (PFA) fixant 
Depolymerised 4% (w/v) PFA, 4% (w/v) sucrose, phenol red indicator, 1 M 
NaOH, 1x Phosphate Buffered Saline (PBS). Final pH should be 7.0 – 7.5. 
 
Phosphate-buffered saline (PBS) 
1.9 mmol/l sodium dihydrogen orthophosphate 1-hydrate, 8.4 mmol/l disodium 
hydrogen orthophosphate 2-hydrate, 150 mmol/l sodium chloride. 
 
DEPC-H20 
0.1% (v/v) diethyl procarbonate in milli-Q water. Mixed overnight then 
autoclaved for 30 minutes at 121ºC. 
 
Cell lines 
The LJ 801 cell line used in these experiments was derived from an ear punch 
taken from a limosine-jersey (LJ) cross-bred steer. 
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3. Results 
 
3.1 Metaphase Zygote NT Results 
 
3.1.1 Metaphase zygote NT 
 
3.1.1.1 Introduction 
For the metaphase zygote NT experiments, the overall objective was to carry out 
the standard NT procedure (as described in section 2.1.10) using zygotes arrested 
in the metaphase stage as recipients for SCNT. Metaphase arrested somatic cells 
were used as donor cells for these experiments.  This work was carried out in an 
attempt to replicate the experiments of Egli, Rosains et al. (2007) in which 
metaphase-arrested mouse zygotes were used as recipients for SCNT. Control 
experiments using MII oocytes as recipients of metaphase arrested somatic donor 
cells were carried out in parallel with the metaphase zygote NT experiments.  
 
3.1.1.2 Fusion parameter comparison 
Several fusion parameters were tested, varying the amplitude, length between the 
two fusion pulses (pulse length) and osmolarity of the fusion buffer. This was 
done in order to find the optimal fusion parameters for the fusion of metaphase 
somatic donor cells into zygotes. In all trials, non-enucleated zygotes 22 hours 
post fertilisation (hpf) were used as recipients for the metaphase donors.  
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The optimal fusion buffer of the two buffers tested was that with an osmolarity of 
205 osm (table 3.1 and table 3.2). From the early trails an amplitude of 450 V and 
two 30 µs pulses gave encouraging results. We trialled these parameters 
extensively and results show fusion of 60% of couplets was achieved. A later 
smaller trial using our standard fusion parameters for somatic G0 or G1 donors 
(600 V amplitude with two 10 µs pulses) revealed a higher rate of successfully 
fused couplets (76.9%) than all other fusion parameters tested (Table 3.2). This 
result, however, was not significant. The fusion parameters used for the 
metaphase zygote NT experiments described in the following section were 450 V 
amplitude with two 30 µs pulses. 
 
Table 3.1 – Fusion Parameter comparison (271 osm buffer) 
Amplitude (V) Pulse Length (µs) No. Fused % Fused 
300 30 0/20 0.0 
375 30 5/20 25.0 
450 30 3/20 15.0 
525 30 4/20 20.0 
 
 
Table 3.2 – Fusion Parameter comparison (205 osm buffer) 
Amplitude (V) Pulse Length (µs) No. Fused % Fused 
375 30 17/40 42.5 
450 10 8/20 40.0 
450 30 48/80 60.0 
450 50 6/20 30.0 
525 30 7/20 35.0 
600 10 10/13 76.9 
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3.1.1.3 Selection of zygotes in metaphase 
Zygotes were classed as being in metaphase by staining with Hoechst 33342 dye 
and illuminating the chromosomes under U.V light on the microscope stage prior 
to enucleation.  
 
During the second metaphase zygote NT experiment, 19 random karyoplasts (the 
enucleated portion of cytoplasm containing the chromosomes) were fixed for 30 
minutes at 4°C in 4% PFA and later examined (by illumination under U.V) to 
determine if the zygotes selected were in fact in metaphase. It was found that 
78.9% of those zygotes enucleated were in metaphase (Table 3.3). Metaphase 
zygote and MII oocyte chromosomes were distinguishable, as the metaphase 
zygote karyoplasts contained two chromatin masts, whereas the MII oocyte 
karyoplasts only contained one metaphase plate. 
 
Table 3.3 – Selection efficiency of metaphase zygotes 
n Metaphase Zygote Interphase Zygote MII Oocyte Other % Metaphase 
19 15 1 2 1 78.9 
 
 
3.1.1.4 Enucleation of metaphase zygotes  
To determine the volume of cytoplasm removed from the metaphase zygotes 
during the enucleation process, 24 random karyoplasts were retained from the 
third metaphase zygote NT trial. These karyoplasts were then photographed, the 
diameter measured and the karyoplast volumes calculated (Table 3.4) using the 
standard spherical volume calculation 4/3 π r3 where r is the radius of the 
karyoplast. A non-enucleated metaphase zygote from the same experiment was 
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also retained and its volume calculated. The average volume removed was 
calculated and finally the average cytoplasmic volume removed from metaphase 
zygotes during enucleation, was found to be 6.5 ± 4.1%. 
 
Table 3.4 – Volume of cytoplasm removed during enucleation 
Karyoplast number Diameter in cm (1.0 cm = 40 µm) Actual Size (µm) Volume (µm3) 
1 1.4 56.0 91952.3 
2 1.4 56.0 91952.3 
3 1.3 52.0 73622.2 
4 1.4 56.0 91952.3 
5 1.3 52.0 73622.2 
6 1.2 48.0 57905.8 
7 1.4 56.0 91952.3 
8 0.8 32.0 17157.3 
9 0.8 32.0 17157.3 
10 0.8 32.0 17157.3 
11 0.8 32.0 17157.3 
12 1.2 48.0 57905.8 
13 0.8 32.0 17157.3 
14 0.8 32.0 17157.3 
15 0.7 28.0 11494.0 
16 1.6 64.0 137258.3 
17 1.3 52.0 73622.2 
18 1.2 48.0 57905.8 
19 1.0 40.0 33510.3 
20 0.8 32.0 17157.3 
21 1.1 44.0 44602.2 
22 1.4 56.0 91952.3 
23 1.4 56.0 91952.3 
24 1.4 56.0 91952.3 
Karyoplast Averages 1.1 45.0 57717.3 
Zygote 2.6 119.0 882347.2 
Standard Deviation of 
Karyoplast volume 0.3 11.2 35935.0 
Volume Removed = 6.5 ± 4.1% 
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3.1.1.5 Metaphase zygote NT development 
Table 3.4 shows a summary of results from the metaphase zygote NT 
experiments, and the control experiments using MII oocytes as recipients. The 
column labelled “n” signifies the number of repeats for each experiment.  
 
The control experiments gave consistent development to blastocyst, with an 
average total development overall of 10.8%.  
 
When enucleated metaphase zygotes were used as recipients of metaphase 
somatic donor cells for NT, no development to blastocyst was observed (Table 
3.5, %TD).  The resulting embryos did not progress past the 8 cell stage of 
development (Table 3.5, n > 8c). 
Recipient n Fused % Fused nCHX nIVC nLSOF n Cleaved % Cleaved n2-8c n > 8c B 1-3 %TD 
MII Oocyte (Control) 5 293/371 79.0a 284 277 126 260 93.9a N.D N.D 30 10.8a
Metaphase Zygote 3 53/106 50.0b N/A 53 21 44 83.0b 15 0 0 0.0b
a,b – Values with different superscripts are significantly different; N.D – Not Determined; CHX – Cycloheximide; IVC – In vitro culture; LSOF – Late synthetic oviduct fluid; B 1-3 – Blastocyst grade 1-3; 
 
 
  
Table 3.5 – Metaphase Zygote NT Development 
8c – 8 cell; %TD - % Total development. 
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 3.1.1.6 Polar body extrusion of NT embryos 
Approximately 24 hours post activation; control NT embryos were examined for 
extrusion of a pseudo polar body (PPB) (table 3.6). The metaphase zygote 
recipients (approximately 26 hours post fusion) were also examined for pseudo 
polar body extrusion.  The proportion of control embryos which did extrude a 
pseudo polar body was 26.7%. None of the metaphase zygote NT embryos had 
extruded a polar body (table 3.6). 
 
Table 3.6 – Polar body extrusion of NT embryos 
Recipient n(IVC) n(PPB) % (PPB) 
MII oocyte 277 74 26.7a
Metaphase zygote 53 0 0.0b
a,b – values with different superscripts differ significantly 
 
3.1.1.7 Analysis of early embryos for correct chromatin distribution 
Early embryos were fixed and analysed at various time periods after fusion. 
     
 Fig 3.1 – MII control Fig 3.2 – Metaphase Zygote 
 
Fig 3.1 shows the control recipient (metaphase II oocyte) 24 hours post fusion to a 
metaphase donor cell. The embryo is at the two cell stage and shows the correct 
chromatin distribution of one nucleus per blastomere. Blastomeres are cells 
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 produced by mitotic division of the zygote following fertilisation. Fig 3.2 shows 
the situation 24 hours post fusion when a metaphase zygote is used as a NT 
recipient for a metaphase donor cell. It can be seen that the chromatin distribution 
in the metaphase zygote recipient (Fig 3.2) is erratic and uneven throughout the 
embryo. Embryos which had ≥ 2 interphase nuclei or > 2 metaphase chromatin 
masses in at least one blastomere (cells which make up the embryo) were classed 
as being abnormal. Quantification of the chromatin distribution in these early 
embryos (Table 3.7, below) shows none of the metaphase zygote NT embryos had 
the correct chromatin distribution 24 hours post fusion. Over half of the MII 
controls had the correct distribution of chromatin at the same time point. 
 
Table 3.7 – Chromatin distribution in early embryos 
Recipient Hours Post Fusion n Embryos n Correct Distribution % Correct Distribution 
Metaphase Zygote 24 17 0 0.0a
MII (Control) 24 12 7 58.3b
a,b – values with different superscripts differ significantly 
 
3.1.1.8 Cleavage of metaphase zygote NT reconstructs 
Metaphase zygote NT reconstructs were placed into IVC and assessed for 
cleavage 3.5 hours after fusion. In all three metaphase zygote NT experiments, 
62.3% of the zygotes had cleaved 3.5 hours post fusion (Table 3.8). None of the 
control NT embryos (MII oocyte recipients) had cleaved 3.5 hours post fusion 
(table 3.8).  My hypothesis was that this early cleavage of the zygotes may be 
contributing to the zygotes having an incorrect distribution of chromatin and so 
delaying cleavage may be beneficial to the development of the embryos. 
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 Table 3.8 – Cleavage of Metaphase Zygote NT reconstructs 
Recipient Hours Post Fusion n n Cleaved % Cleaved 
Metaphase zygote 3.5 53 33 62.3 
MII Oocyte 3.5 277 0 0.0 
 
 
3.1.2 Cytochalasin B treatment of embryos 
 
3.1.2.1 Introduction 
Embryos were treated with Cytochalasin B (CB) post fusion in order to delay 
cleavage of the zygote and potentially achieve correct chromatin distribution in 
the embryos. CB delays cell cleavage by inhibiting formation of the actin 
filaments (MacLean-Fletcher and Pollard, 1980). IVP controls were generated in 
order to find if CB affected the chromatin distribution of standard IVP embryos. 
The embryos were analysed after periods of 4 hours and 17 hours in CB.  The 
metaphase zygote NT embryos were also treated with CB post fusion, before 
washout and placement in to IVC. This was done as a further attempt to achieve 
development to blastocyst using the metaphase arrested zygotes as recipients. 
 
3.1.2.2 CB Treatment of IVP embryos 
Embryos (22 hpf) were fixed and stained with Hoechst 33342 after time periods 
of 4 h and 17 h in CB (the +CB group). These embryos were then analysed for 
correct chromatin distribution under U.V exposure. – CB controls (with media 
containing the DMSO solvent CB is dissolved in) were also included in this 
analysis. Before washout from CB, all embryos were at the one cell stage. 30 
minutes after washout from CB in ESOF medium, almost all of the embryos had 
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 cleaved. This shows CB is effective for delaying embryo cleavage, and that this 
delay in cleavage is reversible. Section 2.2.5 explains the full method for these 
experiments. Percentage figures in brackets indicate the proportion of embryos 
with the correct chromatin distribution of one nucleus (or two condensed 
chromatin masses) per blastomere. In a number of cases, it was unclear whether 
embryos did or did not have a correct chromatin distribution. The group kept in 
CB for the 4 hour period shows a larger proportion of embryos with the correct 
chromatin distribution as compared to the other treatment groups (Table 3.9, +CB 
4 h). In the group treated for 4 h, a greater number of embryos were at the one and 
two cell stages, while the group treated for 17 h had a larger number of embryos 
at the ≥ 3 cell stages. This is expected due to the age of the embryos, i.e. – at 17 h, 
the embryos would normally be at a more advanced stage. 
 
Table 3.9 – CB treatment of IVP embryos 
Treatment n 1c 2c 3c 4c ≥8c Unclear 
+CB 4h 25 
4 
(50%) 
15 
(67%) 
1 
(0%) 
1 
(0%) 
1 
(0%) 
3 
(12%) 
-CB + DMSO 4h 19 
4 
(25%) 
8 
(63%) 
4 
(0%) 
2 
(0%) 
0 
(0%) 
1 
(5%) 
+CB 17h 14 
3 
(33%) 
6 
(50%) 
1 
(100%) 
1 
(0%) 
0 
(0%) 
3 
(21%) 
-CB + DMSO 17h 25 
1 
(0%) 
7 
(43%) 
6 
(0%) 
6 
(33%) 
1 
(0%) 
4 
(16%) 
 
 
3.1.2.3 Effect of CB on development 
Metaphase zygotes used as recipients for NT were treated with CB for the 4 h 
period. Again in these experiments, no cleavage of the embryos was observed 
prior to washout from CB. Also included in this group are the MII oocyte NT 
controls and IVP controls. These controls were included in case development to 
81 
 
 blastocyst was observed in the metaphase zygote group, as the development could 
be compared to standard the control groups. The IVP controls are shown for both 
the 4 h +CB treatment, and the –CB (+ DMSO) treatment (Table 3.10). 
Development to blastocyst was observed in the control MII recipient group. The 
IVP +CB group shows higher development to blastocyst than the IVP –CB group 
(Table 3.10), however this result is not significant. There was still no development 
past the 8-cell stage in the Metaphase Zygote +CB NT group (Table 3.10). 
 
Table 3.10 – CB treatment of metaphase zygote NT embryos 
Treatment nIVC nLSOF n Cleaved % Cleaved n2-8c n > 8c B 1-3 %TD 
+CB IVP 30 10 26 86.7 N.D N.D 5 16.7a
-CB IVP 30 5 27 90.0 N.D N.D 2 6.7a
+CB NT (M-zygote) 17 4 15 88.2 4 0 0 0.0a
-CB NT (MII oocyte) 44 13 32 72.7 N.D N.D 5 11.4a
N.D – Not determined; a,b – values with different superscripts differ significantly 
 
3.1.3 Nocodazole washout of metaphase zygote NT +CB embryos 
 
3.2.3.1 Introduction 
Nocodazole is a drug which arrests the zygotes and cells in metaphase by 
depolymerisation of microtubules (Jordan et al., 1992). Washing the NT embryos 
out of nocodazole and therefore allowing a longer time for the nuclear spindle to 
reform correctly before being placed CB may be beneficial for the embryos. For 
these experiments, NT was carried out in the same manner as in section 3.1.2.3. 
However, post fusion reconstructs were washed out of nocodazole for a period of 
either 30 minutes (group 1) or 60 minutes (group 2). This would allow 
observation of whether washing the reconstructs out of nocodazole would be 
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 beneficial for the embryos and result in development to blastocyst in the 
metaphase zygote NT +CB group. 
 
3.1.3.2 Nocodazole washout (w/o) data for metaphase zygote NT +CB 
embryos 
Embryos produced from the metaphase zygote NT were washed out of 
nocodazole in drops of H199 + 3 mg/ml BSA - nocodazole. The first group was 
washed out of nocodazole for a period of 30 minutes, and the second group for a 
period of 60 minutes. Washing the embryos in this media allows the nuclear 
spindle an extra 30 – 60 minutes to reform in the absence of nocodazole and CB. 
This did not lead to development of the embryos past the 8-cell stage (Table 3.11). 
In this experiment, no embryos developed to a stage worthy of being transferred 
to the LSOF medium on day 5 of IVC. 
 
Table 3.11 – Nocodazole washout of metaphase zygote NT embryos +CB 
 
Treatment nIVC nLSOF n Cleaved % Cleaved n2-8c n > 8c B 1-3 B 1-2 %TD 
30min w/o 26 0 21 80.8 21 0 0 0 0.0 
60min w/o 31 0 25 80.6 25 0 0 0 0.0 
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 3.2 mRNA Analysis Results 
 
3.2.1 Introduction 
The relative mRNA content of TPT1 and BRG1 in zygotes of various stages, as 
well as MII oocytes was analysed using real-time RT PCR. This was carried out 
to observe any differences in the abundance of mRNA between the oocyte and 
zygote samples. It was proposed that those zygote/oocyte stages with a higher 
mRNA concentration of TPT1 or BRG1 would have a greater ability to reprogram 
somatic nuclei. All standard curves were generated using cDNA from LJ801 
bovine fibroblast cells. 
 
3.2.2 18S mRNA analysis 
A standard curve was derived for the 18S primers to calculate the relative 
concentration of 18S mRNA in a sample (sections 2.3.2 and 2.3.3).  
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Reaction 
Efficiency = 1.94  
Fig 3.3 – 18S standard curve. Cp values are plotted and fitted with a logarithmic regression. 
 
Fig 3.3 shows the standard curve for analysis of 18S mRNA. The equation gained 
from this standard curve (y = -3.51476163 x + 6.57468499) was used to determine 
the relative concentration of 18S mRNA in the samples (Tables 3.12 and 3.13). 
The relative concentration of the mRNA from the gene of interest (TPT1 or BRG1) 
was then normalised against the concentration of 18S mRNA in the samples. 18S 
is therefore the “house-keeping” gene, as levels of 18S are assumed to remain 
fairly constant throughout all samples allowing detection of any real differences in 
the levels of the target gene in the samples. 
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 3.2.3 TPT1 mRNA analysis 
Fig 3.4 shows the amplification curves for TPT1 and 18S run simultaneously 
using real–time PCR. The exponential phase (steep portion of the graph) and 
plateau phase (the flat portion at the top of the graph) are clearly visible. Crossing 
point values (Cp’s) were taken from this real-time PCR run and placed into table 
3.12. 
 
 
Fig 3.4 – Amplification plot of TPT1/18S 
 
Fig 3.5 shows the dissociation curves gained for TPT1 and 18S when run 
simultaneously using real-time PCR. It can be seen that there are specific melting 
curves for the products, whereas melting curves for the NTC and RT –ve differ 
vastly from these. The curves confirm a specific product has been produced using 
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 these primers. Melting points for 18S range between 83.09 – 83.38°C and melting 
points for TPT1 range from 88.15 – 88.47°C. 
 
 
RT -ve 
TPT1 Melting 
curves
18S Melting 
curves
NTC
Fig 3.5 – Dissociation curves for TPT1/18S 
 
A standard curve was derived for TPT1 (fig 3.6) to calculate the relative 
concentration of TPT1 in the samples. 
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Reaction 
Efficiency = 1.69  
Fig 3.6 – TPT1 standard curve. Cp values are plotted and fitted with a logarithmic regression. 
 
Fig 3.6 shows the standard curve graph for the TPT1 mRNA analysis. Using the 
equation gained from this graph (y = -4.3176x + 22.033), the relative 
concentration of TPT1 mRNA in the samples analysed was able to be calculated 
(sections 2.3.2 and 2.3.3). 
 
Table 3.12 shows the data gained from the two real-time PCR reactions carried 
out using the cDNA isolated from the zygote and oocyte samples. All reactions 
for the TPT1 primers were carried out simultaneously with 18S (the house-
keeping gene). For each run, the relative concentration of the TPT1 mRNA from 
each zygote stage has been compared to the amount in an MII oocyte and placed 
in the table as the “MII Equivalent” (“MII Equi” in table 3.12). The MII 
equivalent was calculated as a ratio of the relative TPT1 mRNA concentration in 
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the zygote to the relative TPT1 mRNA concentration in the MII oocyte; hence the 
“MII Equi” value for the MII oocyte in table 3.12 shows 1.00. 
89 
Group nPCR (TPT1) CpTPT1 [TPT1] (RU) nPCR (18S) Cp18S [18S] (RU) [TPT1]/[18S] 
MII 
Equi 
MII 1 26.58 0.05 1 15.98 0.002 24.82 1.00 
 2 28.20 0.02 2 18.42 0.000 42.91 1.00 
TII 1 26.96 0.04 1 16.49 0.002 27.09 1.09 
 2 30.56 0.00 2 19.77 0.000 22.47 0.52 
Interphase 1 26.49 0.06 1 15.79 0.002 23.23 0.94 
 2 26.63 0.05 2 17.34 0.001 58.57 1.36 
M-Zygote 1 29.84 0.00631 1 18.94 0.000 20.82 0.84 
 2 27.13 0.03663 2 17.67 0.001 52.56 1.22 
           Table 3.12 – mRNA analysis of TPT1 
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Fig 3.7 – Relative concentration of TPT1 in different stages of embryo development. Error bars 
represent the standard deviation from the two real-time PCR reactions. A statistical analysis 
carried out on this data in the form of a two-tailed t test reveals the data is not significant (values 
do not differ P < 0.05). 
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 3.2.4 BRG1 mRNA analysis 
A standard curve was derived for the BRG1 primers (fig 3.27) to calculate the 
relative concentration of BRG1 mRNA in the samples analysed. 
 
 
Reaction 
Efficiency: 1.89  
Fig 3.8 – BRG1 standard curve. Cp values are plotted and fitted with a logarithmic regression. 
 
Fig 3.8 shows the standard curve generated for the BRG1 mRNA analysis. The 
equation of this curve (y = -2.3485x + 25.177) was used to determine the relative 
concentration of BRG1 in the samples analysed (sections 2.3.2 and 2.3.3). 
Table 3.13 shows the same information as shown in table 3.12, but for the BRG1 
gene. As for the TPT1 mRNA analysis, the real-time PCR carried out on the 
BRG1 gene was normalised using the house-keeping gene 18S. The relative 
concentration of BRG1 in the zygote samples was compared to the amount in a 
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standard MII oocyte and the MII equivalent ratio calculated for all samples as 
done for the TPT1 gene. All PCR experiments were carried out using cDNA from 
the same isolation procedure. 
93 
Group Replicate (BRG1) CpBRG1 [BRG1] (RU)  Replicate 18S Cp18S [18S] (RU) [BRG1]/[18S] MII Equi 
MII 1 25.01 1.11 1 13.59 0.010 110.43 1.00 
  2 28.85 0.09 2 18.42 0.000 216.42 1.00 
TII 1 26.81 0.35 1 15.04 0.004 88.80 0.80 
  2 31.06 0.02 2 19.77 0.000 124.94 0.58 
Interphase 1 25.15 1.02 1 14.00 0.008 131.91 1.19 
  2 29.84 0.05 2 17.34 0.001 56.11 0.26 
M-Zygote 1 29.84 0.00631 1 18.94 0.000 20.82 0.84 
 2 27.13 0.3663 2 17.67 0.001 52.56 1.22 
            Table 3.13 – mRNA analysis of BRG1 
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Fig 3.9 – Relative concentration of BRG1 in different stages of embryo development. Error bars 
represent the standard deviation from the two real-time PCR reactions. A statistical analysis 
carried out on this data in the form of a two-tailed t test revealed the data was not significant 
(values do not differ P < 0.05) 
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 3.3 Immunocytochemistry Results 
 
3.3.1 TCTP Immunocytochemistry 
 
3.3.1.1 Introduction 
TCTP was identified as a putative reprogramming factor, as it has been found to 
activate transcription of key pluripotency genes (OCT-4 and NANOG) in 
transplanted Hela cell nuclei (Koziol et al., 2007). TCTP was also found to be 
present in bovine oocytes with a high potential to reprogram somatic cells (Tani et 
al., 2007). Cells, oocytes and zygotes of various stages were stained with the 
TCTP primary antibody and a fluorescent secondary antibody in order to analyse 
its presence in these samples. The hypothesis was that TCTP would localise to the 
pronuclei of interphase zygotes. 
 
3.3.1.2 Hela cells 
A) B) 
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 C) D) 
  
Fig 3.10 – TCTP ICC on Hela cells. A) Hoechst 3342 nuclear stain. B) TCTP antibody stain.         
C) Merge of figs A and B. D) Negative control. 
 
Reactivity of the TCTP antibody with Hela cells was tested. Hela cells are 
immortal human epithelial cervical cancer cells. The TCTP antibody has been 
tested to cross react with human species. Results gained here show a positive stain 
for TCTP and a cytoplasmic, as well as nuclear distribution of the TCTP protein 
(figs 3.10 C and 3.10 B). The negative control for this ICC is shown in fig 3.10 D) 
and is clearly negative. 
 
3.3.1.3 CCL-44 bovine fibroblast immortalised cell line 
A) B) 
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 C) D) 
                     
Fig 3.11 – TCTP ICC on CCL-44 cells. A) Hoechst 33342 nuclear stain. B) TCTP antibody stain.  
C) Merge of figs A and B. D) Negative control  
 
The TCTP antibody was tested for cross-reactivity with the bovine species by 
carrying out immunocytochemistry on the immortalised bovine fibroblast cell line 
CCL-44 (embryonic bovine trachea cells). A positive result was obtained in these 
samples, showing the antibody does indeed cross react with bovine cells. From the 
image, it is clear that TCTP is distributed in the cytoplasm and nuclei of the 
randomly proliferating CCL-44 cells (figs 3.11 B and 3.11 C). 
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 3.3.1.4 Oocytes and Zygotes 
3.3.1.4.1 MII oocyte 
A) B) 
  
C) 
 
Fig 3.12 – TCTP ICC on MII oocyte. A) Hoechst 33342 nuclear stain. B) TCTP antibody stain.     
C) Negative control. 
 
Fig 3.12 A) shows the Hoechst 33342 staining of the MII oocyte, with the 
condensed metaphase II plate visible (solid arrow). MII oocytes have a uniform 
staining of TCTP throughout, clearly indicating that TCTP is present in the MII 
oocyte (fig 3.12 B). 
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 3.3.1.4.2 Telophase II zygote 
A) B) 
   
C) D)  
  
Fig 3.13 – TCTP ICC on TII zygote. A) Hoechst 33342 nuclear stain. B) TCTP antibody stain.       
C) Merge of figs A and B. D) Negative control. 
 
The Hoechst 33342 stain of the TII zygote (fig 3.13 A) shows the two maternal 
chromatin masses (dashed arrow) and the paternal sperm DNA (solid arrow). It 
can be seen the TCTP stain of the same TII zygote (fig 3.13 B) shows a clear 
localisation of TCTP to the maternal chromatin. There is no staining visible 
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 around the paternal chromatin. When figs 3.13 A) and 3.13 B) are merged (fig 
3.13 C) it can be seen that the TPT1 localises to only one of the two maternal 
chromatin masses 
Further images of TII zygotes were analysed. Figs 3.14 A) and 3.14 B) show a TII 
zygote mounted in the correct orientation on the slide, so that the extruded second 
polar body (PB) is clearly visible (fig 3.14 B). Hoechst 33342 staining shows the 
two maternal chromatin masses (dashed arrow) and the paternal chromatin (solid 
arrow). TCTP staining of the zygotes (fig 3.14 B) shows that TCTP protein 
localises to the second polar body of the TII zygote (as there is a more intense 
signal). 
 
A) B) 
  
PB 
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 C) 
 
 Fig 3.14 – TCTP ICC on TII zygotes showing 2nd PB. A) Hoechst 33342 nuclear stain. B) TCTP 
antibody stain. C) Negative control. 
 
Quantification of the number of TII zygotes with a TCTP localisation to the 
second polar body is shown in table 3.14 below. It can be seen that from 14 TII 
zygotes stained with the TCTP antibody where the second polar body is visible, 
nearly 80% showed a clear localisation of TCTP to the polar body. None showed 
clearly no localisation to the polar body and three which were analysed it was 
unclear whether or not there was a localisation of TCTP to the polar body. 
 
Table 3.14 – Quantification of TII TCTP localisation 
n n Positive n Negative n Inconclusive % Positive 
14 11 0 3 78.6 
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 3.3.1.4.3 Confocal imaging of TII zygotes 
A) B) 
   
PB 
C) D) 
   
PB 
 
 
 
 
 
 
 
103 
 
 E) F)  
  
PB 
Fig 3.15 – Confocal images of a TII zygote showing 2nd PB. A) Hoechst 33342 nuclear stain.       
B) TCTP antibody stain. C) Lamin antibody stain. D) Merge of figs A and B. E) Merge of figs A, 
B and C. F) Negative control.  
 
Confocal microscopy was also used to analyse TII zygotes mounted in the correct 
orientation on the slide so the second polar body (PB) is visible. This high 
resolution analysis confirms that TCTP localises to the second polar body (figs 
3.15 B and 3.15 D). Double staining with Lamin (red) shows that TCTP also co-
localises with lamin (fig 3.15 C). Paternal DNA from the sperm (dashed arrow) 
can be seen from the Hoechst 33342 stain (fig 3.15 A). When merged with the 
image of the TCTP stain (fig 3.15 B), it can be seen that TCTP does not localise 
to the paternal chromatin of the TII zygote (fig 3.15 D). The negative control (fig 
3.15 F) shows some red background staining from the lamin antibody (red), but is 
essentially negative. Fig 3.15 E) shows the TCTP stain co-localises with lamin in 
the second polar body. 
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 3.3.1.4.4 Interphase zygote 
A) B) 
  
C) 
 
Fig 3.16 – TCTP ICC on interphase zygote. A) Hoechst 33342 nuclear stain. B) TCTP antibody 
stain. C) Negative control. 
 
Fig 3.16 A) shows the Hoechst 33342 stain of an interphase zygote, with the two 
large pronuclei clearly visible. From fig 3.16 B) it can be seen the interphase 
zygote stains positively for TCTP, with a small localisation to the plasma 
membrane (possibly an artefact). 
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 3.3.1.4.5 Metaphase zygote 
A) B) 
  
C)  
  
Fig 3.17 – TCTP ICC on metaphase zygote. A) Hoechst 33342 nuclear stain. B) TCTP antibody 
stain. C) Negative control. 
 
Fig 3.17 A) shows the Hoechst 33342 stain of a metaphase zygote with the two 
distinct condensed chromatin masses. The metaphase zygote stains positive for 
TCTP (fig 3.17 B). There looks to be a uniform distribution of the protein, with a 
small localisation to the plasma membrane, which may be an artefact of the 
staining. 
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 3.3.2 BRG1 Immunocytochemistry 
 
3.3.2.1 Introduction 
BRG1 has been identified as necessary for reprogramming human somatic cells 
using Xenopus egg extract. Pluripotency markers (OCT4 and GCAP) were up 
regulated in somatic cells in the presence of BRG1 (Hansis et al., 2004). 
Immunocytochemistry of BRG1 was carried out on Hela cells, bovine cells, 
oocytes and zygotes of various stages to analyse the presence of the protein in 
these samples. The hypothesis was that like TCTP; BRG1 would also localise to 
the pronuclei of interphase zygotes. 
 
3.3.2.2 Hela cells 
A) B)  
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 C) 
 
Fig 3.18 – BRG1 ICC on Hela cells. A) Hoechst 33342 nuclear stain. B) BRG1 antibody stain. C) 
Negative control. 
 
The BRG1 antibody was tested on Hela cells as a positive control to confirm the 
antibody reacts with human cells (a species on which the antibody has been 
tested). Fig 3.18 B) confirms the antibody does react with the Hela cells, showing 
a weak stain throughout the cells. Although this staining is weak and non-specific, 
it is significantly different from the negative control (fig 3.18 C), where only 
weak background staining was observed.  
 
3.3.2.3 CCL-44 cells 
A) B) 
  
C) 
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Fig 3.19 – BRG1 ICC on CCL-44 cells. A) Hoechst 33342 nuclear stain. B) BRG1 antibody stain. 
C) Negative control.  
 
The antibody was tested on the bovine fibroblast cell line CCL-44 (fig 3.19 B) to 
observe if the antibody cross-reacts with the bovine species. It can be seen there is 
no significant difference between the BRG1 antibody stain on the CCL-44 cells 
(fig 3.19 B) and the negative control (fig 3.19 C), as both are essentially black. 
 
3.3.2.4 BRG1 ICC on bovine embryos 
The BRG1 antibody was also tested on a bovine metaphase zygote (fig 3.20 A) to 
confirm the antibody does not react with the bovine species. It can be clearly seen 
that the results for the BRG1 ICC on the bovine zygote are also negative. The 
antibody stain (fig 3.20 B) does not differ from the negative control (fig 3.20 C). 
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 A) B) 
  
C) 
 
Fig 3.20 – BRG1 ICC on bovine zygotes. A) Hoechst 33342 nuclear stain. B) BRG1 antibody 
stain. C) Negative control. 
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 3.3.3 HDAC1 Immunocytochemistry 
 
3.3.3.1 Introduction 
Histone Deacetylase 1 (HDAC1) has been shown to have important affects on the 
development of preimplantation mouse embryos, by acting as a repressor of 
transcription in 2-cell mouse embryos (Ma and Schultz, 2008). HDAC1 
immunocytochemistry was carried out on Hela cells, bovine cells, oocytes and 
zygotes of various stages and its presence in these samples was analysed. HDAC1 
has been shown to localise to the chromosomes of MII mouse oocytes as well as 
the nucleus and pronucleus of mouse zygotes (Ma and Schultz, 2008). Due to 
these observations, a similar nuclear localisation was expected in the bovine cells. 
 
3.3.3.2 Hela cells 
A) B) 
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 C) 
 
Fig 3.21 – HDAC1 ICC on Hela cells. A) Hoechst 33342 nuclear stain. B) HDAC1 antibody stain. 
C) Negative control. 
 
The staining of Hela cells shows a clear positive result for the presence of 
HDAC1 (fig 3.21 B). Localisation of the staining looks to be essentially nuclear 
for the HDAC1 antibody. 
 
3.3.3.3 CCL-44 cells 
A) B) 
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 C) 
 
Fig 3.22 – HDAC1 ICC on CCL-44 cells. A) Hoechst 33342 nuclear stain. B) HDAC1 antibody 
stain. C) Negative control. 
 
Fig 3.22 A) shows the Hoechst 33342 stain on a population of randomly 
proliferating CCL-44 bovine cells. The HDAC1 antibody stain fig (3.22 B) shows 
there is the same nuclear staining present in the CCL-44 bovine cells as seen in 
Hela cells. This confirms that the antibody reacts with both the bovine and human 
species, and is therefore suitable to use on bovine zygotes and oocytes. 
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 3.3.3.4 Oocytes and Zygotes 
3.3.3.4.1 MII oocyte 
A) B) 
  
C) 
 
Fig 3.23 – HDAC1 ICC on MII oocyte. A) Hoechst 33342 nuclear stain. B) HDAC1 antibody 
stain. C) Negative control. 
 
Fig 3.16 A) shows the Hoechst 33342 stain of a metaphase II oocyte, with the 
condensed metaphase plate clearly visible. From the respective HDAC1 antibody 
stain of this oocyte (fig 3.23 B), it can be seen the HDAC1 stain is very similar to 
the TCTP stain (fig 3.12 B). Both have a strong positive signal throughout the 
oocyte. 
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 3.3.3.4.2 Telophase II zygote 
A) B) 
  
C) 
 
Fig 3.24 – HDAC1 ICC on TII zygote. A) Hoechst 33342 nuclear stain. B) HDAC1 antibody stain. 
C) Negative control. 
 
Fig 3.24 A) shows the Hoechst 33342 stain of a TII zygote, with two maternal 
chromatin masses (dashed arrow), and the paternal sperm genome (solid arrow). 
The respective HDAC1 antibody stain of this zygote can be seen in fig 3.24 B). It 
can be seen there is a strong staining of HDAC1 which localises to one of the 
maternal chromatin masses of the zygote (which could be the extruded second 
polar body). Also, the HDAC1 protein is clearly absent from the paternal DNA. 
115 
 
 This is almost identical to the TCTP staining observed in the TII zygotes (fig 3.14 
B). To confirm if the HDAC1 protein does localise to the second polar body of the 
TII zygote, zygotes mounted in the correct orientation so that the second polar 
body can be seen were analysed (below). 
 
A) B) 
  PB 
C) 
 
Fig 3.25 – HDAC1 ICC on TII zygote showing 2nd PB. A) Hoechst 33342 nuclear stain.               
B) HDAC1 antibody stain. C) Negative control. 
 
Fig 3.25 A) shows the Hoechst 33342 stain of a TII zygote, with the second polar 
body (PB) is clearly visible. The respective HDAC1 stain of this zygote (fig 3.25 
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 B) shows there is a strong localisation of the HDAC1 protein to the second polar 
body of the TII zygote. Also there seems to be some localisation to the plasma 
membrane (possibly an artefact). This is similar what was observed for the TCTP 
ICC performed on TII zygotes with an extruded second PB (fig 3.14 B). 
 As with TCTP, numbers of TII zygotes with a HDAC1 localisation to the second 
polar body were recorded. Results are shown in table 3.15 below. From 9 TII 
zygotes stained with the HDAC1 antibody where the second polar body is visible, 
7 showed a clear localisation of HDAC1 to the polar body. There were none 
where no localisation to the second polar body was evident, and two where it was 
unable to be concluded whether there was a localisation or not. 
 
Table 3.15 – Quantification of TII HDAC1 localisation 
n n Positive n Negative n Inconclusive % Positive 
9 7 0 2 77.8 
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 3.3.3.4.3 Confocal imaging of TII zygotes 
A) B) 
  
PB 
C) D)  
  
PB
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 E) 
 
Fig 3.26 - Confocal images of a TII zygote showing 2nd PB. A) Hoechst 33342 nuclear stain 
(maternal chromatin). B) HDAC1 antibody stain. C) Merge of figs A and B. D) Hoechst 33342 
nuclear stain (paternal chromatin) and HDAC1 stain. E) Negative control. 
 
Figs 3.26 A) – E) show images of a TII zygote viewed under the confocal 
microscope. In figs 3.26 B) and C), the extruded second polar body is clearly 
visible. The Hoechst 33342 stain of the TII zygote with the two maternal 
chromatin masses clearly visible (dashed arrow) is shown in fig 3.26 A). Fig 3.26 
B) shows the respective HDAC1 antibody stain of the zygote in fig 3.26 A). It can 
be seen that there is a stronger staining signal (orange) in the extruded second 
polar body of this zygote. A merge of figs 3.26 A) and 3.26 B) shows the stronger 
staining signal of the HDAC1 is found around the second maternal chromatin 
mass of the zygote which is extruded as the polar body. Fig 3.26 D) shows a 
merged image of the paternal chromatin (solid arrow) from a TII zygote (stained 
with Hoechst 33342) and the respective HDAC1 stain of this zygote. It can be 
seen from this image that the HDAC1 protein does not localise to the paternal 
chromatin (there is no HDAC1 signal around the paternal chromatin). This is 
identical to the results from the TCTP staining (fig 3.13 B) of the TII zygote, 
which shows TCTP does not localise to the paternal chromatin. 
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 3.3.3.4.4 Interphase zygote 
A) B) 
  
C) 
 
Fig 3.27 – HDAC1 ICC on interphase zygote. A) Hoechst 33342 nuclear stain. B) HDAC1 
antibody stain. C) Negative control. 
 
Fig 3.27 A) shows the Hoechst 33342 stain of an interphase zygote, with two 
pronuclei (cloudy in appearance) visible. There seems to be a fairly uniform stain 
of HDAC1 throughout the interphase zygote (fig 3.27 B). HDAC1 staining of the 
zygote is similar to the TCTP stain (fig 3.16 B) with a small apparent localisation 
to the plasma membrane observed. 
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 3.3.3.4.5 Metaphase zygote 
A) B) 
  
C) 
 
 Fig 3.28 – HDAC1 ICC on metaphase zygote A) Hoechst 33342 nuclear stain. B) HDAC1 
antibody stain. C) Negative control. 
 
Fig 3.21 A) shows the Hoechst 33342 stain of a metaphase zygote with the two 
condensed chromatin masses. The staining of a metaphase zygote with HDAC1 
(fig 3.28 B) is similar to the staining of TCTP observed in the metaphase zygote 
(fig 3.17 B). There is a clear positive stain evident with an apparent small 
localisation to the plasma membrane. 
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 4. Discussion 
 
4.1 Metaphase zygote NT experiments 
This study demonstrates that blastocysts can be produced by NT of a metaphase 
donor cell into an enucleated metaphase II oocyte. Tani, Kato et al. (2001) also 
produced blastocysts using somatic mitotic donor cells for NT, with an average 
efficiency of ~ 30%; three times higher than development achieved in my 
experiments (10.8%). This may be due to the different methodologies used by 
Tani, Kato et al. (2001). In their experiments, fused NT embryos were activated 
using a combination of an electrical pulse (rather than a calcium ionophore) and 
exposure to CHX. Also, Tani and colleagues used bovine cumulus cells as donors, 
rather than LJ 801 fibroblasts used in my experiments. It is also unclear from the 
Tani, Kato et al. (2001) study if all media used during the NT procedure contained 
nocodazole to ensure the donor cells would not exit metaphase. This could mean 
some of the observed development may have resulted from recipients fused to a 
donor cell of a stage other than metaphase. Differences in techniques of the 
operator carrying out the procedure (between myself and Tani, Kato et al. 2001) 
may have also contributed to these observed differences in results. 
 
Tani, Kato et al. (2001) discovered that whether or not the early embryo extruded 
a second polar body, had no effect on the in vitro developmental potential of that 
embryo. However, those embryos which did not extrude a second polar body were 
found to be tetraploid and therefore could not develop into live calves (Tani et al., 
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 2001). Five diploid embryos produced using metaphase arrested donor cells were 
transferred to recipient cows, and one live calf was produced. This proves that NT 
using metaphase donor cells can produce cloned embryos which have the 
potential to develop into normal calves (Tani et al., 2001). In my experiments 
using MII oocytes as NT recipients for metaphase donor cells, polar body 
extrusion was found to be low (~ 27%), but the result is similar to the rate of 
second polar body extrusion seen by Tani, Kato et al. (2001) (26.5%). 
Karyotyping of 20 embryos (data not shown) indicated 18 of the blastocysts 
produced in my experiments were clearly not diploid and therefore may not have 
the potential to develop into normal live cloned offspring (Booth et al., 2003). 
  
Several fusion parameters were trialled in order to find the optimal conditions for 
fusion of metaphase arrested somatic donor cells into metaphase zygotes. Despite 
this, fusion rates for metaphase arrested somatic cells into enucleated metaphase 
zygotes were low. The fusion rates for metaphase arrested somatic cells into MII 
oocytes were higher, and similar to the results achieved by Tani, Kato et al. 
(2001). However, the fusion efficiency achieved in my control NT experiments is 
still considerably lower than fusion efficiency for control NT experiments in the 
Schurmann, Wells et al. (2006) paper which used serum starved donor cells 
(Schurmann et al., 2006). This may be due to the larger size of the metaphase 
donor cells used in my experiments. The larger cytoplasmic volume removed 
from metaphase zygotes during enucleation as compared to MII oocytes (Oback et 
al., 2003) may also have contributed to the drop in fusion efficiency 
(Zakhartchenko et al., 1997). Membrane changes which occur in the oocyte 
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 during fertilisation and subsequent activation (Runft et al., 2002) may also be 
responsible for the lower observed fusion efficiency. 
 
During the second metaphase zygote NT experiment, the selection efficiency of 
metaphase zygotes was analysed. It was found approximately 80% of all NT 
reconstructs produced in these experiments used a metaphase zygote recipient. 
This figure may be influenced by my method of selecting the zygotes, and one can 
assume that over time my selection efficiency of metaphase zygotes would 
improve. The remaining 20% were either MII oocytes, interphase zygotes or the 
stage of the recipient could not be determined from the appearance of the 
chromatin. It can be assumed enucleated interphase zygotes mistakenly used as 
recipients would not develop (Wakayama et al., 2000) and therefore not produce a 
false positive result. However, MII cytoplasts used as recipients for these 
experiments could develop to blastocyst, giving a misleading result. If this was the 
case, it would be expected at least some development or polar body extrusion 
would be observed. Numbers of embryos placed into IVC from these experiments 
may have been too small to observe any potential development in the metaphase 
zygote recipient NT group.  
 
From the third metaphase zygote NT experiment, the average volume of 
cytoplasm removed from the zygotes during enucleation was calculated. This 
volume was found to be considerably more than the volume removed from MII 
oocytes during the standard zona-free (zona-pellucida removed) NT procedure. 
Oback, Wiersema et al. (2003) found the average volume removed from MII 
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 oocytes during standard zona-free enucleation to be 1.8 ± 0.3% (Oback et al., 
2003). It is possible the higher volume of cytoplasm removed when enucleating 
the metaphase zygotes (as compared to the MII oocytes) may have contributed to 
halting development of the embryos at the 8-cell stage. Reducing the volume of 
bovine oocytes used has recipients for NT by 50% has been shown to decrease 
development to blastocyst (Westhusin et al., 1996), however, reducing the volume 
of the oocyte by 5% was shown to have no significant effect on development to 
blastocyst (Westhusin et al., 1996). In my experiments, although the average 
volume of cytoplasm removed from the embryos was less than 50%, it was greater 
than 5% and so this reduction may have compromised development of the 
resulting embryos. Westhusin, Collas et al. (1996) also found a significantly lower 
cell number was present in blastocysts produced from oocytes with 50% of their 
cytoplasm removed. Again, a 5% reduction in the cytoplasmic volume of NT 
recipient cytoplasts shows no significant difference in blastocyst cell number 
compared to the controls. The cytoplasmic volume removed when enucleating 
zona-free metaphase zygotes is more than three times the volume removed when 
enucleating zona-free MII oocytes, and is also much more variable. The rationale 
that a reduction in cytoplasmic volume of bovine oocytes decreases development 
may also apply to bovine zygotes. 
 
Blastocysts could not be produced by NT of a metaphase donor cell into an 
enucleated metaphase zygote. Delaying cleavage of the embryos by exposure to 
CB for four hours was successful and appeared to have a beneficial effect on the 
chromatin distribution in the early embryos. Exposure of embryos to CB for a 
period of four hours did not have any significant affect on total development to 
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 blastocyst. Development in both the + and – CB groups was observed to be low, 
which may be due to the low number of embryos produced in these experiments. 
Another potential reason as to why no development to blastocyst was observed 
may have been due to exposure of the embryos to nocodazole throughout the NT 
procedure, which ensures the zygotes and cells remain in metaphase. Nocodazole 
arrests cells in metaphase by depolymerisation of the microtubule spindles of the 
cell (Jordan et al., 1992). Washing the reconstructs out of nocodazole and 
therefore allowing more time for the spindle to reform in the presence of CB may 
be beneficial to embryo development. No development was observed past the 8c 
stage in embryos washed out of nocodazole before treatment with CB and culture. 
 
All development in the metaphase zygote recipient NT experiments was halted at 
the 8-cell stage. Possibly the main reason behind this may be due to the early 
cleavage of the NT zygotes post fusion, which would not allow for correct 
chromatin organisation. Egli, Rosains et al. (2007) observed correct chromosome 
segregation and cleavage within 90 – 150 minutes in the mouse. In my 
experiments over 60% of the reconstructs had cleaved 3.5 hours post fusion, 
however correct chromosome segregation was not observed, therefore these 
events post NT seem to occur differently in bovine. Although CB was effective in 
delaying cleavage, it may also have inhibited reformation of the nuclear spindle. 
Ploidy errors resulting from no extrusion of a pseudo polar body may also explain 
why no development was observed past the 8-cell stage. 
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 Embryonic genome activation occurs at the 8 – 16-cell stage in bovine embryos 
(Camous et al., 1986) and this may not have occurred in these experiments, 
meaning no new transcription would be initiated in the early embryo. Another 
potential explanation as to why no development was observed past the 8-cell stage 
may be due to the exposure of the zygotes to U.V light during the enucleation 
procedure. In the Egli et al. 2007 paper in which blastocysts were produced using 
metaphase zygotes as recipients for NT, the microtubule spindle was visualised 
for enucleation using either Hoffman modulation contrast (which allows phase 
gradients to be visualised) or optical birefringence (where the double refraction of 
light allows chromosomes to be visualised). Visualising chromosomes by staining 
with Hoechst 33342 dye and exposure to U.V was found to compromise 
development (Egli et al., 2007). In my experiments the chromosomes were 
visualised for enucleation by staining with Hoechst 33342 dye and illumination 
under U.V light. Exposure times to U.V of greater than 30 seconds have been 
shown to affect membrane integrity, methionine incorporation and therefore to 
alter protein synthesis in bovine oocytes (Smith, 1993). 
 
4.2 mRNA analyses of candidate reprogramming factors 
TPT1 mRNA was found to be expressed in all samples analysed. This is in 
agreement with current findings that TPT1 is expressed in all mammalian tissues 
analysed thus far (Sanchez et al., 1997). It has also been previously described that 
TPT1 mRNA is present in bovine oocytes from the germinal vesicle (GV) to MII 
stage as well as during preimplantation development stages from the pronucleus 
to blastocyst (Tani et al., 2007). From the mRNA analysis of the TPT1 gene, it 
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 was unable to be concluded if this gene would have a major influence on the 
reprogramming ability of the oocytes and zygotes analysed. No significant 
differences were observed in the relative concentrations of TPT1 mRNA between 
the various samples. 
 
BRG1 mRNA was also found in all samples analysed by real-time PCR, which is 
in agreement with current knowledge. BRG1 is known to be expressed in mouse 
oocytes (Bultman et al., 2000) and was also found to be expressed in zygotes 
(Bultman et al., 2006).  However, results from this analysis of BRG1 mRNA were 
also inconclusive. 
 
Results gained from real-time PCR reactions for the TPT1 and BRG1 genes may 
be inconclusive due to the relatively low reaction efficiencies gained when 
producing the standard curves for the primers. The ideal reaction efficiency for a 
PCR reaction is 2.0 (meaning the amount of transcript is exactly doubled each 
cycle). My reaction efficiencies for standard curves were consistently less than 2.0, 
which could lead to errors being produced when calculating the relative 
concentrations of the genes in the samples. Recent evidence suggests house-
keeping genes may vary between samples (Dheda et al., 2004) and so variability 
in the concentration of 18S in these samples may also have contributed to errors in 
the calculated relative concentrations. 
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 Statistical analysis was carried out on these results in the form of a two-tailed t 
test. This test revealed no significant differences in the relative concentrations of 
the target genes between the samples. The differences in the MII equivalents 
between the samples were also not significant. Although mRNA transcript levels 
of TPT1 remained constant throughout the various samples, some stages of 
recipients used for NT have differing abilities to reprogram an introduced somatic 
donor cell. This may be due to a different localisation of the TCTP protein 
between the NT recipients. Analysis of HDAC1 mRNA was not carried out as 
primers for this gene were not acquired. 
 
4.3 ICC Analyses of cells, MII oocytes and zygotes 
Immunocytochemistry performed on the TCTP, BRG1 and HDAC1 proteins 
allowed observation of the distribution of the protein the gene translates to 
throughout the various sample stages. Bovine cells and zygotes stained with the 
BRG1 antibody produced negative results. One explanation for this may be that 
the mRNA present in the zygote and oocyte samples (as shown from real-time 
RT-PCR results) is not translated to the BRG1 protein in the bovine cells or 
embryos. The positive result for BRG1 on human Hela cells shows the BRG1 
mRNA is translated in this sample. Another explanation for the negative result of 
BRG1 ICC on bovine samples is that the chosen antibody does not cross-react 
with the bovine species. This is plausible as the portion of the protein the antibody 
reacts with (first 15 amino acids of the N-terminus) in human is not identical to 
the bovine equivalent (94% homology). 
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 Results from ICC of TCTP on human and bovine cells as well as show a 
cytoplasmic distribution of the TCTP protein, with some nuclear localisation 
observed (certainly not absent from all cell nuclei). These results are in agreement 
with the description that TCTP is a cytoplasmic protein (Li et al., 2001), although 
some nuclear localisation has been observed (Yubero et al., 2008). Tani, Shimada 
et al. (2007) found that phosphorylated TCTP is present in bovine oocytes before 
GVBD until the MII stage and was seen to decline gradually after activation by 
ionomycin and CHX or 6-DMAP. My results also show a clear presence of TCTP 
in the bovine MII oocyte. Localisation of TCTP in bovine zygotes has not been 
previously described. These results show a positive stain for TCTP in all stages of 
zygote, with a clear localisation of the protein to the maternal chromatin in the 
second polar body of TII zygotes. 
 
MII mouse oocytes stained with an HDAC1 antibody show a localisation of the 
protein to the metaphase chromosomes (Ma and Schultz, 2008). This result is 
contradictory to my observations on bovine MII oocytes, where a uniform stain of 
HDAC1 can be seen throughout the entire oocyte. ICC performed on mouse 
zygotes by Ma and Schultz (2008) shows that following fertilisation, the HDAC1 
protein remains present in the pronucleus and nucleus, up to the blastocyst stage. 
My results show no nuclear localisation of HDAC1 to the pronuclei of interphase 
zygotes or to the chromosomes of metaphase zygotes in bovine. In the TII zygotes, 
however, there is a localisation of the HDAC1 protein to the maternal chromatin 
of the second polar body. This finding has not been described previously, possibly 
as zygotes at the TII stage are seldom examined. 
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 Both the TCTP and HDAC1 proteins have very similar patterns of staining 
throughout the oocytes as well as the various zygote stages. In interphase and 
metaphase zygotes there is a uniform stain throughout the zygote, with a slight 
localisation to the plasma membrane. This observed localisation to the plasma 
membrane may however been an artefact due to an artificially high concentration 
of the antibody present around the edges of the sample (“edge effect”). Both 
proteins were shown localise to the maternal chromatin of TII zygotes, and remain 
absent from the paternal chromatin. More specifically, they seem to localise to the 
maternal chromatin mass which is extruded from the zygote as the second polar 
body. Almost all TII zygotes which were mounted on the slide in such a way as to 
allow clear viewing the extruded second polar body, showed a clear staining 
intensity in this region. Confocal microscopy of these samples confirmed this 
result, and double staining zygote samples with lamin and TCTP revealed that 
TCTP also co-localises with lamin (main components of the nuclear envelope) in 
the second polar body of TII zygotes. The ultimate result from these findings is 
that these putative reprogramming factors (TCTP and HDAC1) localise to the 
second polar body of TII zygotes, which is then extruded from the zygote. 
Although there were no significant differences in the relative concentrations of the 
TPT1 gene between the zygote stages, the localisation of the protein produced by 
the translated mRNA is clearly unique in the TII zygotes. 
 
The result from immunocytochemistry performed on the TII zygotes is surprising, 
as it is known that enucleated TII zygotes used as recipients for NT results in 
improved in vivo development of offspring (Schurmann et al., 2006). Since TCTP 
(potentially required for correct reprogramming of the donor nucleus) localises to 
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 the second polar body, this candidate reprogramming factor would be enucleated 
and discarded during the IVF-NT procedure used by Schurmann, Wells et al. 
(2006). One would assume that this loss of this potentially beneficial 
reprogramming factor would result in poorer development of the IVF-NT 
embryos. However the observed in vivo development results from Schurmann, 
Wells et al. (2006) contradict this. One reason why this occurs may be due to 
TCTP becoming obsolete once fertilisation has occurred. Once the sperm has 
entered the oocyte and a zygote is formed, activation of the POU5F1 and NANOG 
pluripotency genes by TCTP (Koziol et al., 2007) may no longer be required. This 
theory may also confirm the suggestion that artificial activation of NT embryos 
contributes to poorer in vivo development (Schurmann et al., 2006), as artificial 
activation of the reconstructs may lead to incorrect localisation or extrusion of 
TCTP. This means the introduced donor nucleus may not be reprogrammed 
correctly to an embryonic state. Removal of HDAC1 from the TII zygote during 
the IVF-NT procedure may be beneficial for development of the resulting 
embryos. HDAC1 is known to initiate a transcriptionally repressive state in 
preimplantation mouse embryos (Ma and Schultz, 2008). This may mean 
repressing transcription of pluripotency genes such as POU5F1 and NANOG, and 
therefore not allowing correct epigenetic reprogramming of the donor genome. 
Exposure of NT embryos to the HDAC inhibitor TSA, results in greater 
development of the embryos (Kishigami et al., 2006) which confirms HDAC is 
inhibitory to their development and justifies that removal of HDAC1 may be 
beneficial to embryo development.  
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 4.4 Conclusions 
These results suggest metaphase zygotes are not suitable as recipients for SCNT 
using the current methodologies. Use of a longer wavelength dye to visualise the 
chromatin or employing an alternative enucleation technique may lead to success 
in future experiments. This study showed there were no significant differences 
between the relative concentrations of TPT1 and BRG1 mRNA in zygotes or MII 
oocytes. The ICC analysis of the zygotes and oocytes revealed TCTP and HDAC1 
proteins seemed to be evenly distributed throughout the MII oocytes, metaphase 
zygotes and interphase zygotes. However these proteins clearly showed a 
localisation to the second polar body of telophase II zygotes. This has never been 
described previously. Future work on these candidate reprogramming factors must 
be carried out in order to unearth the significance of this finding. 
 
4.5 Future work 
Future metaphase zygote NT experiments conducted to achieve development in 
the metaphase zygote recipient group may include the use of a longer wavelength 
fluorochrome (such as SYBR 14) to visualise the chromosomes of metaphase 
zygotes during enucleation. Staining chromosomes of oocytes with longer 
wavelength fluorochromes results in greater development to blastocyst when 
compared with Hoechst 33342 staining followed by U.V illumination (Dominko 
et al., 2000). An alternative enucleation technique such as chemical enucleation 
(Moura et al., 2008) could be employed to reduce the amount of cytoplasm 
removed during the procedure. These experiments should also use larger numbers 
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 of fused reconstructs, approximately the same number as used in the MII control 
NT experiments. 
 
Analysis of the HDAC1 mRNA could be carried out on the different zygote stages 
as well as the MII oocytes in order to observe any differences in the levels of the 
HDAC1 gene between the samples. This would allow comparison of the gene 
expression pattern of HDAC1 to those of BRG1 and TPT1. Gene expression levels 
of other candidate reprogramming factors such as nucleoplasmin (Betthauser et al., 
2006; Tamada et al., 2006), germ cell proteins FRGY2a and FRGY2b (Gonda et 
al., 2003) and the nuclear protein N1/N2 (Kleinschmidt et al., 1986) could also be 
analysed in zygotes and oocytes. 
In continuation of the ICC analysis, western blotting could be performed on the 
various stages of zygote as well as the MII oocytes to quantify any differences in 
the abundance of protein between the samples. ICC could be carried out on 
isolated second polar bodies of the TII zygotes, as well as the first polar bodies of 
the MII oocytes. It is not known if the TCTP and HDAC1 proteins also localise to 
the first polar body of MII oocytes. Western blotting could be carried out on the 
isolated polar bodies also. 
 
Telophase II nuclear transfer (TNT) experiments could be trialled in an attempt to 
increase the concentration of candidate reprogramming factors in NT embryos, 
leading to greater cloning efficiency. TNT experiments would involve removing 
the maternal chromatin (including the second polar body) from TII zygotes by 
enucleation. The intact karyoplasts would be retained and fused into MII oocytes. 
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 Once the candidate reprogramming factors had dissociated into the cytoplasm, the 
remaining chromatin would then be enucleated and a somatic donor cell fused into 
the oocyte as per the standard NT procedure. A control group of standard NT 
embryos would also be generated and the development to blastocyst of each group 
compared. 
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